A Dark Vector Cognition product
10-K comparison

Dexcom (DXCM) 10-K risk factor changes: FY2025 vs FY2024

The 2025-12-31 10-K against the 2024-12-31 one, compared heading by heading and sentence by sentence.

Item 1A129 rewritten81 added37 removed978 unchanged

All filing items895 rewritten434 added449 removed2,406 unchanged

Read the changesGo to Item 1A

Dexcom Form 10-K, every itemFY2025, filed 12 February 2026, against FY2024, filed 18 February 2025FY2025 on sec.govFY2024 on sec.govRead this filing

Summary

counted, not written

New Item 1A headings (1)

  1. We cannot guarantee that the 2025 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.

Removed Item 1A headings (0)

Every FY2024 risk factor heading is still here, word for word or reworded.

Reworded Item 1A headings (2)
  1. If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, [added: including responding to the FDA warning letter,] or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.
  2. Climate change may have [removed: a long-term] [added: an adverse] impact on our business.

A heading is new when no FY2024 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.

Sentences by item

24 items, with every count and a link to each item that changed
ItemAddedRemovedRewrittenUnchangedPage headers and footers changed
Item 1A. RISK FACTORS81371299780
Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS2731681150
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK115190
Item 1. BUSINESS7476904430
Item 3. LEGAL PROCEEDINGS4046780
Cover and table of contents99281030
Item 1B. UNRESOLVED STAFF COMMENTS00010
Item 1C. CYBERSECURITY004400
Item 2. PROPERTIES27810
Item 4. MINE SAFETY DISCLOSURES00020
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES916120
Item 6. [RESERVED]00000
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA13000
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE00010
Item 9A. CONTROLS AND PROCEDURES229340
Item 9B. OTHER INFORMATION80110
Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS00020
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE00180
Item 11. EXECUTIVE COMPENSATION00100
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS00010
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE00020
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES00020
Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES5214390
Item 16. FORM 10-K SUMMARY1752345245940

Underlined words on a shaded ground are new in FY2025; struck-through words were in FY2024. Sentences that are wholly new or wholly gone are labelled rather than marked.

Item 1A. RISK FACTORS

129 rewritten, 81 added, 37 removed, 978 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

Refer to our disclaimer regarding forward-looking statements at the beginning of [removed: Part I, Item 1 of] this Annual Report on Form 10-K.*

Rewritten

We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to [added: future reimbursement changes under Medicare and] pricing pressure from managed care organizations and other third-party payors.

Rewritten

Most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of the G6, [removed: G7] [added: G7, G-7 15 Day, Dexcom One,] and Dexcom [removed: One.][added: ONE+.]

Rewritten

[removed: To the extent these] cost containment efforts are not offset by greater patient access to our products, our revenue may be reduced and our business may be harmed.

Rewritten

[removed: The Centers for Medicare & Medicaid Services, or CMS,] [added: CMS] provides coverage for “Therapeutic Continuous Glucose Monitors” as durable medical equipment eligible for coverage under Medicare Part B.

Rewritten

Medicare does not cover any items or services that are not “reasonable and necessary.” [removed: Medicare covers the CGM system, which includes supplies necessary for] [added: In order to be covered under] the [removed: use] [added: DME benefit, one component] of the [removed: device, under] [added: CGM system must meet] the [removed: Durable Medical Equipment, or DME, benefit category.][added: criteria for a durable medical device.]

Rewritten

To date, the receiver satisfied [removed: this] [added: these] criteria.

Rewritten

As of December 31, [removed: 2024,] [added: 2025,] the eight largest private third-party payors in the United States, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices.

Rewritten

[removed: In addition, in the] United States, existing single-point finger stick devices used by people with diabetes are generally reimbursable for all or part of the product cost by Medicare or other third-party payors, which may be perceived as more advantageous for consumers.

Rewritten

In addition, [removed: 2025 will bring a new] [added: the change in] presidential [removed: administration, which] [added: administration in 2025 has caused and] may [removed: shift] [added: continue to cause shifts in] health policy priorities, including potential impacts on Medicare coverage and reimbursement.

Rewritten

Also, the trends toward managed healthcare in the United States, which we expect to [removed: continue in 2025 and beyond,] [added: continue,] and legislative efforts intended to reduce the cost of [added: government insurance programs could significantly influence the purchase of healthcare services and products and may result in lower prices for our products or the exclusion of our products from reimbursement programs.]

Rewritten

In the ordinary course of [removed: our business] [added: business,] we enter into collaborative arrangements with third parties to expand into new markets, including with insulin device manufacturers to integrate our CGM technology into the third parties’ insulin delivery systems.

Rewritten

[added: In the event of such a termination, we may be required to devote] additional resources to product development and commercialization, we may need to cancel some development programs and we may face increased competition.

Rewritten

[removed: If and when we receive FDA or other regulators’ marketing authorization for, and begin] commercialization of, our next-generation CGM systems, we expect most patients will migrate onto those systems.

Rewritten

- our G6 and G7 systems prompt the user to replace the sensor no later than the tenth day, [added: and our G7 15 Day prompts the user to replace the sensor no later than the fifteenth day,] which might make it expensive for users;

Rewritten

In addition to the risks outlined above, our [removed: G6, G7, Dexcom One, and Stelo systems] [added: CGMs] are more invasive than many other self-monitored glucose testing systems, including single-point finger stick devices, and people with diabetes and those seeking to optimize metabolic health may be unwilling to insert a sensor in their body, especially for those with diabetes if their current diabetes management involves no more than two finger sticks per day.

Rewritten

[added: Moreover,] people with diabetes and those seeking to optimize metabolic health may not perceive the benefits of CGM and people with diabetes may be unwilling to change their current treatment regimens.

Rewritten

[removed: If we are] unable to do so, we may not be able to generate product revenue from our international sales efforts.

Rewritten

If our CGM systems do not achieve and maintain an adequate level of acceptance by people with diabetes, those seeking to optimize metabolic health, healthcare professionals, including physicians, and [removed: third party] [added: third-party] payors, our future revenue may be reduced and our business may be harmed.

Rewritten

We have [removed: recently] experienced manufacturing and inventory challenges for G7 [added: in the past] that [removed: have resulted, and may continue to result from time to time,] [added: resulted] in disruptions in our ability to supply certain markets, including in the U.S. and other countries.

Rewritten

We will need to adequately predict the market demand for our [removed: products, remedy our recent manufacturing challenges,] [added: products] and increase our manufacturing capacity by a significant factor over the current level to meet or exceed the anticipated market demand by product.

Rewritten

We [added: are] also [removed: commenced construction of] [added: building] a new facility in Ireland to scale up manufacturing capacity.

Rewritten

Our ability to scale manufacturing capacity is subject to numerous risks and uncertainties, and may lead to variability in product quality or reliability, increased construction timelines, as well as resources required to design, [added: install and maintain manufacturing equipment, among others, all of which can lead to unexpected delays in manufacturing output.]

Rewritten

Additionally, the majority of our [added: manufacturing] operations are conducted at facilities located in [removed: San Diego, California,] Mesa, Arizona, and [removed: Malaysia.][added: Malaysia and limited manufacturing operations in San Diego, California.]

Rewritten

However, a natural or man-made disaster, such as fire, flood, earthquake, act of terrorism, cyber-attack or other disruptive event, such as a public health emergency, could cause substantial delays in our operations, damage, [removed: destroy or limit our manufacturing equipment, inventory, or records and cause us to incur additional expenses.]

Rewritten

Earthquakes are of particular significance since our [added: headquarters and limited] manufacturing facilities in California are located in an earthquake-prone area.

Rewritten

Wildfires are also increasingly common in southern California and present risk to our [added: headquarters and limited] manufacturing [removed: operations.][added: operations in San Diego, California.]

Rewritten

If we experience manufacturing difficulties or disruptions, [removed: or if we fail to remedy our recent manufacturing and inventory challenges,] it could result in insufficient inventory, increased costs, immediate shortages in product or component supply, and decreased sales, any of which may harm our business.

Rewritten

In some cases, our agreements with these and other suppliers can be terminated by [added: either party upon short notice.]

Rewritten

- switching components may require product redesign and submission to the FDA or international regulator of new applications (such as new 510(k) submissions or PMA supplements) which could significantly [removed: delay production;]

Rewritten

If any supplier, service provider or business partner violates laws or implements unethical practices, there could be disruptions to our supply chain, cancellation of our orders, [added: or] a termination of the relationship with the partner or damage to our reputation, and the FDA or other regulators could seek to hold us responsible for such violations.

Rewritten

Some of our U.S distributors are focused on accessing underrepresented regions and or third-party payors that contract exclusively with distributors in the United States, while some of our international distributors call directly on healthcare providers [removed: and patients to market and sell our products.]

Rewritten

Certain of our distribution agreements generated 10% or more of our total revenue during the twelve months ended December 31, [removed: 2024.][added: 2025.]

Rewritten

In selling our G6, [added: G7,] G7 [added: 15 Day, Dexcom One] and Dexcom [removed: One,] [added: ONE+,] we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic [removed: plc’s Diabetes Group;] [added: (MiniMed);] Roche Diabetes Care, a division of Roche Diagnostics; privately-held LifeScan, Inc.; [removed: and] Ascensia Diabetes [removed: Care,] [added: Care; and other smaller market entrants,] each of which manufactures and markets products for the single-point finger stick device market.

Rewritten

Medtronic [added: (MiniMed)] and other third parties have developed or are developing insulin pumps integrated with CGM systems that provide, among other things, the ability to suspend insulin administration while the user’s glucose levels are low and to automate basal and bolus insulin dosing.

Rewritten

Our operations in countries outside the United States, which accounted for approximately 28% of our revenue for the twelve months ended December 31, [removed: 2024,] [added: 2025,] are accompanied by certain financial and other risks.

Rewritten

We have a significant presence in the [removed: European Union,] [added: EU,] as well as significant sales in the [removed: European Union,] [added: EU,] such that any changes in tax laws in the [removed: European Union] [added: EU] could impact our business.

Rewritten

The overall impact of such legislation in [removed: European Union] [added: EU] member states is uncertain, and our business and financial condition could be adversely affected by any laws impacting our tax rate.

Rewritten

Following a 2016 referendum of voters in the United Kingdom, or the [removed: U.K,] [added: U.K.,] to exit from the [removed: European Union,] [added: EU,] or the E.U., the U.K. left the E.U. on January 31, 2020, which began a transition period that ended on December 31, 2020.

Rewritten

Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the trade and cooperation agreement or otherwise, could prevent us from marketing our CGM systems in the U.K. and/or the [removed: E.U.] [added: EU] and restrict our ability to generate revenue and achieve and sustain profitability.

New in FY2025

Additionally, we may experience pricing pressure if our products are increasingly subject to competitive bidding processes, which include substantial costs and managerial time to prepare bids and proposals for contracts that may not be awarded to us or may be split among competitors.

New in FY2025

For example, in June 2025, the Centers for Medicare & Medicaid Services published a proposed rule that would subject continuous glucose monitors to the competitive bidding process, which could negatively impact our reimbursement and result in price decreases.

New in FY2025

In late 2025, CMS extended the DMEPOS competitive bidding program to include our CGMs and receivers, with contracting beginning in 2027 and payment changes taking effect in 2028.

New in FY2025

Under the program, DMEPOS suppliers compete to become Medicare contract suppliers by submitting bids to furnish certain items in CBAs.

New in FY2025

CMS anticipates that ten (10) contracts will be awarded for CGMs.

New in FY2025

However, while the competitive bidding program previously used CBAs for contract awards, CMS determined that for CGMs and certain other DME, a RID CBA was more appropriate.

New in FY2025

It remains to be seen whether CGMs will be covered under a single, nationwide RID CBA or whether regional RID CBAs will be established.

New in FY2025

In any event, the bid process is expected to result in lower Medicare reimbursement for CGM systems, particularly because CMS is changing the pricing under the RID CBA by setting a single payment amount for covered items at the 75th percentile of the winning bids, rather than using the maximum winning bid.

New in FY2025

Further, CMS has reclassified CGMs and insulin infusion pumps to items that require frequent and substantial servicing and will phase in monthly rental payments for these items.

New in FY2025

CMS will bundle the rental amount for the receiver device with payment for the supplies and accessories in the new payment amount.

New in FY2025

The bid limit will be monthly fee schedule amounts for the supplies plus the average purchase fee schedule amounts for the CGM receiver device divided by 60 (intended to capture the 5-year useful life of the device.) As a result, we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028.

New in FY2025

CMS is required by law to recompete these contracts at least once every three years and to roll out the competitive bidding process nationally or adjust prices in non-competitive bidding areas to match competitive bidding prices.

New in FY2025

The implementation of the competitive bidding program is expected to result in reduced Medicare payment for CGMs in both competitive bidding areas and non-competitive bidding areas.

New in FY2025

Additionally, the new bidding system will contain a “country of origin” question to obtain information on where products are manufactured; however, it is unclear how CMS intends to use this information.

New in FY2025

Given that we maintain offshore manufacturing facilities, country of origin reporting could have an impact on our business.

New in FY2025

Competitive bidding could negatively impact our reimbursement and result in price decreases.

New in FY2025

To the extent these

New in FY2025

On July 4, 2025, President Trump signed the budget reconciliation bill (entitled “One Big Beautiful Bill Act”, or the Bill) to meet spending targets aimed at funding the Administration’s domestic priorities that includes significant changes to the Medicaid program.

New in FY2025

Congressional Budget Office, or CBO, preliminary estimates show that the Medicaid provisions would reduce Medicaid spending by $1 trillion and will increase the number of people without health insurance by at least 11.8 million by 2034.

New in FY2025

Some key proposed changes to the Medicaid Program include, but are not limited to: work requirements; cost sharing of up to $35 per service on expansion adults who exceed the official poverty threshold; stricter eligibility requirements for non-U.S. citizens; requirements for states to conduct eligibility redeterminations at least every six months for Medicaid expansion adults; and prohibitions on states from establishing any new provider taxes or from increasing the rates of existing taxes, among other changes.

New in FY2025

Decreased federal funding and stricter eligibility requirements may result in more restrictive Medicaid programs at the state level and fewer individuals eligible for coverage, which could have an adverse impact on the number of individuals who seek to use our products and services.

New in FY2025

For instance, changes to the ACA included in the Bill, including shortening enrollment periods and eliminating automatic reenrollment, could reduce ACA enrollment.

New in FY2025

We expect material changes in health policy, enforcement initiatives, and coverage and reimbursement for health care items and services from the Trump Administration and Congress.

New in FY2025

In addition, in the

New in FY2025

As discussed above, the Bill included significant changes to federal Medicaid funding and ACA enrollment requirements, all of which are expected to result in decreased Medicaid reimbursement and loss of coverage for individuals under Medicaid and ACA plans.

New in FY2025

If and when we receive FDA or other regulators’ marketing authorization for, and begin

New in FY2025

- loss or reduction of insurance coverage for individuals, resulting in higher cost obligations for users with respect to their purchase of our products;

New in FY2025

If we are

New in FY2025

We are also aware of companies outside the traditional medical device sector that are attempting to develop competitive products and services, including for the general health and wellness, or population health space.

New in FY2025

Some of the companies developing or marketing competing devices are large and well-known publicly traded companies.

New in FY2025

Such competitors may benefit from guidance issued on January 6, 2026 by the FDA’s Center for Devices and Radiological Health that effectively broadens the range of products that may be considered “general wellness devices,” including wearables that provide readings around bodily functions and vital signs such as heart rate, blood pressure, and blood glucose.

New in FY2025

From time to time, the FDA conducts inspections of our facilities and may issue Form 483 findings related to our operations and may issue warning letters or take other administrative or enforcement actions asserting noncompliance with FDA laws and regulations.

New in FY2025

In March 2025, we received an FDA warning letter following inspections of our facilities in San Diego, California, and Mesa, Arizona.

New in FY2025

In the warning letter, the FDA cited deficiencies in the response letters sent by us to the FDA following the Form 483, List of Investigational Observations that was delivered to us in connection with the inspection of our San Diego, California facility that occurred from October 2024 through November 2024, and the inspection of our Mesa, Arizona facility that occurred in June 2024.

New in FY2025

The warning letter describes observed non-conformities in manufacturing processes and our quality management system.

New in FY2025

We take the matters identified in the warning letter seriously and have submitted responses to the Form 483 and to the FDA warning letter.

New in FY2025

While the warning letter does not restrict our ability to produce, market, manufacture or distribute products, require recall of any products, nor restrict our ability to seek FDA 510(k) clearance of new products, we may fail to satisfy these regulatory requirements to the FDA’s satisfaction, and any failure to do so could result in the foregoing occurring.

New in FY2025

While we intend to undertake certain corrective actions and provide regular updates to the FDA in order to meet the requirements set forth by FDA in the warning letter, we cannot give any assurances that the FDA will be satisfied with our response or as to the date we expect to resolve the matters included in the FDA warning letter.

New in FY2025

Until the issues cited in the warning letter are resolved to the FDA’s satisfaction, additional legal or regulatory action may be taken without further notice, including as described above.

New in FY2025

The potential effect of the warning letter and these other events can in some cases be difficult to quantify and could harm our reputation and cause our product sales and profitability to suffer.

Dropped from FY2024

In order to be covered under this benefit, one component of the CGM system must meet the criteria for a durable medical device.

Dropped from FY2024

government insurance programs could significantly influence the purchase of healthcare services and products and may result in lower prices for our products or the exclusion of our products from reimbursement programs.

Dropped from FY2024

In the event of such a termination, we may be required to devote

Dropped from FY2024

Moreover,

Dropped from FY2024

While we are currently working to remedy such challenges, we cannot predict when such manufacturing and inventory challenges will be remedied.

Dropped from FY2024

install and maintain manufacturing equipment, among others, all of which can lead to unexpected delays in manufacturing output.

Dropped from FY2024

As further described in the risk factor above, we have recently experienced manufacturing and inventory challenges that have resulted, and may continue to result from time to time, in disruptions in our ability to supply certain markets, including in the U.S. and other countries.

Dropped from FY2024

either party upon short notice.

Dropped from FY2024

Medtronic markets and sells one or more standalone glucose monitoring products both internationally and in the United States.

Dropped from FY2024

It remains unclear what, if any, additional modifications will be made to this legislation or how it will be interpreted.

Dropped from FY2024

May 2018.

Dropped from FY2024

including sales, billing, customer service, procurement and supply chain, manufacturing, and distribution.

Dropped from FY2024

such laws, and potentially be awarded a share of any damages or penalties ultimately awarded to the applicable government body.

Dropped from FY2024

The potential effect of these events can in some cases be difficult to quantify.

Dropped from FY2024

If any of these actions were to occur, it would harm our reputation and cause our product sales and profitability to suffer.

Dropped from FY2024

inventory to excess or obsolescence charges, which could have an adverse effect on our business, financial condition and operating results.

Dropped from FY2024

These include changes that may reduce

Dropped from FY2024

We have been involved in various patent infringement actions in the past.

Dropped from FY2024

For example, we and certain Abbott entities previously served complaints for patent infringement, validity, and other patent-related actions against each other in multiple jurisdictions, inside and outside the United States.

Dropped from FY2024

See “Legal Proceedings” in Part I, Item 3 below for more information.

Dropped from FY2024

licenses could prevent us from manufacturing and selling our products, which would have a significant adverse impact on our business.

Dropped from FY2024

materials or activities to constitute improper promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.

Dropped from FY2024

objectives, including the commercialization of our current products and the development and introduction of additional products.

Dropped from FY2024

The U.S. government enacted comprehensive tax legislation that included significant changes to the taxation of business entities.

Dropped from FY2024

These changes included, among others, (I) a permanent reduction to the corporate income tax rate, (ii) a partial limitation on the deductibility of business interest expense, (iii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain rules designed to prevent erosion of the U.S. income tax base) and (iv) a one-time tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate.

Dropped from FY2024

On December 20, 2021, the OECD released Pillar Two Model Rules defining the global minimum tax rules, which contemplate a 15% minimum tax rate.

Dropped from FY2024

The OECD continues to release additional guidance on these rules and the Framework calls for law enactment by OECD and G20 members to take effect in 2024 or 2025.

Dropped from FY2024

For example, under the Coronavirus Aid, Relief, and Economic Security Act of 2020, or CARES Act, which amended certain provisions of the Tax Cuts and Jobs Act of 2017, or TCJA, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back.

Dropped from FY2024

The TCJA, as amended by the CARES Act, also provides that NOLs from tax years that began after December 31, 2017 may offset no more than 80% of current taxable income annually for taxable years beginning after December 31, 2020.

Dropped from FY2024

Additionally, in June 2024, the State of California enacted S.B. 167, which suspends the use of NOLs for the tax period from January 1, 2024 to December 31, 2026 for net business income of $1.0 million or more, as well as limits the utilization of research and development tax credits to $5.0 million each year.

Dropped from FY2024

The State of California also passed S.B. 175 to provide for a potential early sunset of NOLs in either 2025 or 2026 if necessary.

Dropped from FY2024

In May 2023, we completed an offering of approximately $1.25 billion aggregate principal amount of 0.375% senior convertible notes due 2028, or 2028 Notes, which offering we refer to as the 2023 Notes Offering.

Dropped from FY2024

We refer to the 2020 Notes Offering and the 2023 Notes Offering, collectively, as the Notes Offerings, and we refer to the 2025 Notes and the 2028 Notes, collectively, as the Notes.

Dropped from FY2024

or by agreements governing our indebtedness outstanding at the time, including our Credit Facility.

Dropped from FY2024

economic, financial, competitive and other factors beyond our control.

Dropped from FY2024

If one or more holders elect to convert their Notes, unless

Dropped from FY2024

the accuracy, adequacy or completeness of the disclosure.

An excerpt. Shown here: 40 of 129 rewritten, 40 of 81 added and all 37 removed. The counts are complete. For every sentence, read Item 1A. RISK FACTORS in the FY2025 filing and the FY2024 filing.

Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

68 rewritten, 27 added, 31 removed, 115 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

| | | | We are a medical device company primarily focused on the design, development and commercialization of [removed: continuous glucose monitoring, or CGM,] [added: CGM] systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world. We received approval from the [removed: Food and Drug Administration, or FDA,] [added: FDA] and commercialized our first product in 2006. We launched our latest generation systems, the [removed: Dexcom G6 integrated Continuous Glucose Monitoring System, or G6,] [added: G7] in [removed: 2018,] [added: 2023,] and [removed: we launched] the [removed: Dexcom G7, or G7,] [added: G7 15 Day] in [removed: 2023.] [added: late 2025.] In August 2024, we launched Stelo, our [removed: new] biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries. | | |

Rewritten

| | | | Partnerships: We [removed: also] continue to [removed: pursue and] support [removed: development] partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. With the introduction of Stelo, we are also pursuing and supporting development partnerships with consumer technology product companies that seek to provide metabolic health insights to their customers. | | |

Rewritten

[removed: Estimates associated with pharmacy] [added: Pharmacy] rebates are the most significant component of [removed: our] variable consideration estimates [added: included in the calculation of the transaction price] and most at risk for material adjustment because of the time delay between the recording of the pharmacy rebate and its ultimate settlement, an interval that generally ranges from 30 to 90 days, but can last up to one year.

Rewritten

An increase or decrease of 1% in our estimate of products sold subject to rebate during [removed: 2024,] [added: 2025,] holding all other assumptions constant, would increase or decrease revenue by approximately [removed: $38.7] [added: $50.1] million.

Rewritten

[removed: For more information, see] [added: See] Note [removed: 1 “*Organization and Significant Accounting Policies—Revenue Recognition*”] [added: 4 “*Debt*”] to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form [removed: 10-K.][added: 10-K for more information on the Amended Credit Agreement.]

Rewritten

We assess the value of our inventory on a quarterly basis and write down [removed: those] inventories [added: to the lower of their cost or net realizable value] based on quality control [removed: testing] data, obsolescence, or [removed: in] excess [removed: of] [added: relative to] our forecasted [removed: demand to the lower of their cost or net realizable value.][added: demand.]

Rewritten

[removed: If] [added: Conversely, if] actual [removed: market] conditions are more favorable than anticipated, inventory previously written down may be sold, resulting in lower cost of sales and higher income from operations than expected in that period.

Rewritten

Significant judgment is required in the determination of [added: the expected outcome (i.e.,] whether a potential loss is probable, reasonably possible, or [removed: remote] [added: remote),] as well as in the determination of whether a potential exposure is reasonably estimable.

Rewritten

We base our judgments on the best information available at the [removed: time.][added: time and regularly reassess as new facts emerge.]

Rewritten

| Key Highlights for fiscal [removed: 2024] [added: 2025] include the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Rewritten

We ended fiscal [removed: 2024] [added: 2025] with cash, cash equivalents and short-term marketable securities totaling [removed: $2.58] [added: $2.00] billion.

Rewritten

For discussion related to the results of operations and changes in financial condition for fiscal [removed: 2023] [added: 2024] compared to fiscal [removed: 2022] [added: 2023] refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our [removed: 2023] [added: 2024] Annual Report on Form 10-K, which was filed with the SEC on February [removed: 8, 2024.][added: 18, 2025.]

Rewritten

| Twelve Months Ended December 31, [removed: 2024] [added: 2025] Compared to Twelve Months Ended December 31, [removed: 2023] [added: 2024] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Rewritten

| | | | Twelve Months Ended December 31, | | | | | | | | | | | | | | | | | | | | | | | | [removed: 2024] [added: 2025] - [removed: 2023] [added: 2024] | | | | | | | | |

Rewritten

| *(In millions, except per share amounts)* | | | [removed: 2024] [added: 2025] | | | | | | % of Revenue (1) | | | | | | [removed: 2023] [added: 2024] | | | | | | % of Revenue (1) | | | | | | $ Change | | | | | | % Change | | |

Rewritten

| Revenue | | | $ | [removed: 4,033.0] [added: 4,662.0] | | | | | 100.0 | | % | | | | $ | [removed: 3,622.3] [added: 4,033.0] | | | | | 100.0 | | % | | | | $ | [removed: 410.7] [added: 629.0] | | | | | [removed: 11] [added: 16] | | % |

Rewritten

| Cost of sales | | | [removed: 1,594.8] [added: 1,860.1] | | | | | | [removed: 39.5] [added: 39.9] | | % | | | | [removed: 1,333.4] [added: 1,594.8] | | | | | | [removed: 36.8] [added: 39.5] | | % | | | | [removed: 261.4] [added: 265.3] | | | | | | [removed: 20] [added: 17] | | % |

Rewritten

| Gross profit | | | [removed: 2,438.2] [added: 2,801.9] | | | | | | [removed: 60.5] [added: 60.1] | | % | | | | [removed: 2,288.9] [added: 2,438.2] | | | | | | [removed: 63.2] [added: 60.5] | | % | | | | [removed: 149.3] [added: 363.7] | | | | | | [removed: 7] [added: 15] | | % |

Rewritten

| Research and development | | | [removed: 552.4] [added: 599.1] | | | | | | [removed: 14] [added: 13] | | % | | | | [removed: 505.8] [added: 552.4] | | | | | | 14 | | % | | | | [removed: 46.6] [added: 46.7] | | | | | | [removed: 9] [added: 8] | | % |

Rewritten

| Selling, general and administrative | | | [removed: 1,285.8] [added: 1,291.0] | | | | | | [removed: 32] [added: 28] | | % | | | | [removed: 1,185.4] [added: 1,285.8] | | | | | | [removed: 33] [added: 32] | | % | | | | [removed: 100.4] [added: 5.2] | | | | | | [removed: 8] [added: —] | | % |

Rewritten

| Total operating expenses | | | [removed: 1,838.2] [added: 1,890.1] | | | | | | [removed: 46] [added: 41] | | % | | | | [removed: 1,691.2] [added: 1,838.2] | | | | | | [removed: 47] [added: 46] | | % | | | | [removed: 147.0] [added: 51.9] | | | | | | [removed: 9] [added: 3] | | % |

Rewritten

| Operating income | | | [removed: 600.0] [added: 911.8] | | | | | | [removed: 15] [added: 20] | | % | | | | [removed: 597.7] [added: 600.0] | | | | | | [removed: 17] [added: 15] | | % | | | | [removed: 2.3] [added: 311.8] | | | | | | [removed: —] [added: 52] | | % |

Rewritten

| Other [removed: income (expense),] [added: income,] net | | | [removed: 109.0] [added: 176.6] | | | | | | [removed: 3] [added: 4] | | % | | | | [removed: 112.7] [added: 109.0] | | | | | | 3 | | % | | | | [removed: (3.7)] [added: 67.6] | | | | | | [removed: (3)] [added: 62] | | % |

Rewritten

| Income before income taxes | | | [removed: 709.0] [added: 1,088.4] | | | | | | [removed: 18] [added: 23] | | % | | | | [removed: 710.4] [added: 709.0] | | | | | | [removed: 20] [added: 18] | | % | | | | [removed: (1.4)] [added: 379.4] | | | | | | [removed: —] [added: 54] | | % |

Rewritten

| Income tax expense [removed: (benefit)] | | | [removed: 132.8] [added: 252.1] | | | | | | [removed: 3] [added: 5] | | % | | | | [removed: 168.9] [added: 132.8] | | | | | | [removed: 5] [added: 3] | | % | | | | [removed: (36.1)] [added: 119.3] | | | | | | [removed: (21)] [added: 90] | | % |

Rewritten

| Net income | | | $ | [removed: 576.2] [added: 836.3] | | | | | [removed: 14] [added: 18] | | % | | | | $ | [removed: 541.5] [added: 576.2] | | | | | [removed: 15] [added: 14] | | % | | | | $ | [removed: 34.7] [added: 260.1] | | | | | [removed: 6] [added: 45] | | % |

Rewritten

| Basic net income per share | | | $ | [removed: 1.46] [added: 2.14] | | | | | | | | | | | $ | [removed: 1.40] [added: 1.46] | | | | | | | | | | | $ | [removed: 0.06] [added: 0.68] | | | | | [removed: 4] [added: 47] | | % |

Rewritten

| Diluted net income per share | | | $ | [removed: 1.42] [added: 2.09] | | | | | | | | | | | $ | [removed: 1.30] [added: 1.42] | | | | | | | | | | | $ | [removed: 0.12] [added: 0.67] | | | | | [removed: 9] [added: 47] | | % |

Rewritten

Other [removed: income (expense),] [added: income,] net

Rewritten

Other [removed: income (expense),] [added: income,] net consists primarily of interest and dividend income on our cash, cash equivalents and short-term marketable securities portfolio, foreign currency transaction gains and losses [removed: due to] [added: resulting from] the effects of foreign currency fluctuations, realized and unrealized gains and losses on [added: marketable and non-marketable] equity investments, [added: including changes in fair value,] and interest expense related to our senior convertible notes.

Rewritten

| Twelve Months Ended December 31, [removed: 2024] [added: 2025] Compared to Twelve Months Ended December 31, [removed: 2023] [added: 2024] | | | | | | | | | | | | | | |

Rewritten

[removed: ![6](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231_g4.jpg)][added: ![6](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231_g4.jpg)]

Rewritten

| | | | [removed: | | |] Twelve Months Ended December 31, | | | | | | | | | | | | | | | | | | | | | | | | [removed: 2024 - 2023] | | | | | | | | | [added: | | | | | | | | | | | |]

Rewritten

| | | | | | | Twelve Months Ended December 31, [removed: 2024] [added: 2025] Compared to Twelve Months Ended December 31, [removed: 2023] [added: 2024] | | |

Rewritten

| Revenue | | | | | | The revenue increase was primarily driven by increased sales volume of our disposable sensors due to the continued growth of our worldwide customer base. We added approximately [removed: 500,000 -] 600,000 [added: - 700,000] net [removed: users,] [added: customers,] excluding Stelo customers, to our worldwide customer base in [removed: 2024.] [added: 2025.] The increase [removed: in revenue] was offset by pricing headwinds due to greater rebate eligibility and channel mix. [removed: Disposable sensor and other revenue comprised approximately 95% of total revenue and Reusable Hardware revenue comprised approximately 5% of total revenue for the twelve months ended December 31, 2024. Disposable sensor and other revenue comprised approximately 90% of total revenue and Reusable Hardware revenue comprised approximately 10% of total revenue for the twelve months ended December 31, 2023.] | | |

Rewritten

| Cost of sales & Gross profit | | | | | | Cost of sales and gross profit increased primarily due to an increase in sales volume driven by the addition of approximately [removed: 500,000 -] 600,000 [added: - 700,000] net [removed: users,] [added: customers,] excluding Stelo customers, to our worldwide customer base in [removed: 2024.] [added: 2025.] The decrease in gross profit margin percentage in [removed: 2024] [added: 2025] compared to [removed: 2023] [added: 2024] was primarily driven by [removed: product and channel mix changes, higher freight costs, and non-cash charges including a $22.7 million inventory build charge, and $20.6 million in inventory damaged in transit and certain] [added: inefficiencies associated with ensuring supply availability,] build configurations that lowered production [removed: yield.] [added: yield, and total replacement costs.] | | |

Rewritten

| | | | | | | Twelve Months Ended December 31, [removed: 2024] [added: 2025] Compared to Twelve Months Ended December 31, [removed: 2023] [added: 2024] | | |

Rewritten

| Research and development expense | | | | | | Research and development expense increased primarily due to [removed: $20.5] [added: $37.3] million in [added: higher] compensation and related [removed: costs due to higher headcount, $11.2 million in clinical trials, supplies and other support costs, and $5.9 million in software and data] costs. We continue to believe that focused investments in research and development are critical to our future growth and competitive position in the marketplace, and to the development of new and updated products and services that are central to our core business strategy. | | |

Rewritten

| Income tax expense | | | | | | The income tax expense recorded for the twelve months ended December 31, [removed: 2024] [added: 2025] was primarily attributable to income tax expense from normal, recurring [removed: operations, partially offset] [added: operations increased] by [removed: excess tax benefits] [added: shortfalls] recognized for share-based compensation for employees, net of nondeductible executive compensation, [removed: the Verily milestone payment,] [added: offset by] the [removed: impacts of certain foreign] tax [removed: return filings and generation] [added: benefit related to the commencement] of [removed: research and development] [added: our Malaysia] tax [removed: credits.] [added: holiday.] The income tax expense recorded for the twelve months ended December 31, [removed: 2023] [added: 2024] was primarily attributable to income tax expense from normal, recurring operations, [removed: as well as income taxes related to an intra-entity transfer of certain intellectual property] partially offset by excess tax benefits recognized for share-based compensation for [removed: employees (net] [added: employees, net] of [removed: disallowed] [added: nondeductible] executive [removed: compensation) and] [added: compensation,] the Verily milestone payment, [added: the impacts of certain foreign tax return filings] and generation of research and development tax credits. The [removed: decrease] [added: increase] in our effective tax rate for the twelve months ended December 31, [removed: 2024] [added: 2025] compared to the same period in [removed: 2023] [added: 2024] is primarily attributable to impacts of [removed: the prior year tax restructuring and] [added: shortfalls on share-based compensation, a non-recurring benefit related to] the Verily milestone [removed: payment.] [added: payment during 2024, offset by the tax benefit related to the commencement of our Malaysia tax holiday.] | | |

Rewritten

Our cash, cash equivalents and short-term marketable securities totaled [removed: $2.58] [added: $2.00] billion as of December 31, [removed: 2024.][added: 2025.]

New in FY2025

Inventory Reserves

New in FY2025

Significant judgment is applied in evaluating quality control testing data, assessing whether non-conforming inventory can be remediated, reworked, or otherwise partially recovered, and in some cases, estimating our forecasted demand.

New in FY2025

Similarly, if remediation outcomes differ from our assumptions, additional adjustments may be necessary.

New in FY2025

At December 31, 2025, a 1% change in the inventory reserve expense recognized during the year would not have resulted in a material change in inventory and cost of goods sold.

New in FY2025

We evaluate the nature of the claim, the stage of the proceedings, prior case outcomes, and input from legal counsel.

New in FY2025

| $4.66 billion | | | | | | | | | $2.80 billion | | | | | | | | | $911.8 million | | | | | | | | | $836.3 million | | | | | | | | | $1.44 billion | | |

New in FY2025

| up 16% from 2024 | | | | | | | | | up 15% from 2024 | | | | | | | | | up 52.0% from 2024 | | | | | | | | | up 45% from 2024 | | | | | | | | | up 46% from 2024 | | |

New in FY2025

| 2025 | | | | | | | | | | | | | | | | | | 2024 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2025

| *(In millions)* | | | United States | | | | | | International | | | | | | Total | | | | | | United States | | | | | | International | | | | | | Total | | | | | | | | | | | | | | |

New in FY2025

| Distributor | | | $ | 3,195.7 | | | | | $ | 763.3 | | | | | $ | 3,959.0 | | | | | $ | 2,824.4 | | | | | $ | 605.7 | | | | | $ | 3,430.1 | | | | | | | | | | | | | |

New in FY2025

| Direct | | | 139.2 | | | | | | 563.8 | | | | | | 703.0 | | | | | | 65.4 | | | | | | 537.5 | | | | | | 602.9 | | | | | | | | | | | | | | |

New in FY2025

| Total revenue | | | $ | 3,334.9 | | | | | $ | 1,327.1 | | | | | $ | 4,662.0 | | | | | $ | 2,889.8 | | | | | $ | 1,143.2 | | | | | $ | 4,033.0 | | | | | | | | | | | | | |

New in FY2025

| Selling, general and administrative expense | | | | | | Selling, general and administrative expense increased primarily due to $83.7 million in higher compensation and related costs, $9.1 million in higher software and data costs, offset by $87.2 million in lower legal expense primarily related to a patent infringement lawsuit that was settled in December 2024. | | |

New in FY2025

| Other income, net | | | | | | Other income, net, increased primarily due to $79.5 million in higher net gains on equity investments and $8.7 million in higher net foreign currency gains, offset by $21.5 million in lower interest and dividend income on our cash, cash equivalents, and marketable securities portfolio. The decrease in interest income was primarily related to a change in market interest rates, as well as a decrease in the average invested balances compared to the same period in 2024. | | |

New in FY2025

As we continue to expand our manufacturing sites in Ireland and Malaysia, we will be subject to additional foreign exchange currency risk.

New in FY2025

The decrease in cash, cash equivalents and short-term marketable securities was primarily due to the repayment of our unsecured senior convertible notes due 2025, or 2025 Notes, upon maturity in November 2025.

New in FY2025

| *(In millions)* | | | 2025 | | | | | | 2024 | | | | | | $ Change | | |

New in FY2025

| Net cash provided by operating activities | | | $ | 1,440.7 | | | | | $ | 989.5 | | | | | $ | 451.2 | |

New in FY2025

| Net cash provided by (used in) investing activities | | | 536.0 | | | | | | (207.5) | | | | | | 743.5 | | |

New in FY2025

| Net cash used in financing activities | | | (1,686.4) | | | | | | (734.8) | | | | | | (951.6) | | |

New in FY2025

| Effect of exchange rate changes on cash, cash equivalents and restricted cash | | | 21.5 | | | | | | (7.4) | | | | | | 28.9 | | |

New in FY2025

| Increase in cash, cash equivalents and restricted cash | | | $ | 311.8 | | | | | $ | 39.8 | | | | | $ | 272.0 | |

New in FY2025

| | | | | | | | | | Twelve Months Ended December 31, 2025 Compared to Twelve Months Ended December 31, 2024 | | |

New in FY2025

| Operating Cash Flows | | | | | | | | | $260.1 million increase in net income | | |

New in FY2025

| | | | $196.5 million increase in net non-cash adjustments primarily due to adjustments to deferred income taxes, partially offset by gains on equity investments | | | | | | | | |

New in FY2025

| Financing Cash Flows | | | | | | | | | $250.0 million decrease in cash used to repurchase our common stock | | |

New in FY2025

| | | | $1.21 billion increase in cash used upon the maturity of our 2025 Notes | | | | | | | | |

Dropped from FY2024

Excess and Obsolete Inventory

Dropped from FY2024

Our estimates of forecasted demand are based upon our analysis and assumptions including, but not limited to, expected product lifecycles, product development plans and historical usage by product.

Dropped from FY2024

We review the status of each significant matter quarterly and assess our potential financial exposure.

Dropped from FY2024

As additional information becomes available, we reassess the potential liability related to our pending claims and litigation and may revise our estimates.

Dropped from FY2024

Any revision of our estimates of potential liability could have a material impact on our financial position and operating results.

Dropped from FY2024

| $4.03 billion | | | | | | | | | $2.44 billion | | | | | | | | | $600.0 million | | | | | | | | | $576.2 million | | | | | | | | | $989.5 million | | |

Dropped from FY2024

| up 11% from 2023 | | | | | | | | | up 7% from 2023 | | | | | | | | | up 0.4% from 2023 | | | | | | | | | up 6% from 2023 | | | | | | | | | up 32% from 2023 | | |

Dropped from FY2024

| | | | | | | 2024 | | | | | | | | | | | | 2023 | | | | | | | | | | | | Change in Revenues | | | | | | | | |

Dropped from FY2024

| *(In millions)* | | | | | | Revenue | | | | | | % of Total | | | | | | Revenue | | | | | | % of Total | | | | | | $ | | | | | | % | | |

Dropped from FY2024

| United States | | | | | | $ | 2,889.8 | | | | | 72% | | | | | | $ | 2,625.3 | | | | | 72% | | | | | | $ | 264.5 | | | | | 10% | | |

Dropped from FY2024

| International | | | | | | 1,143.2 | | | | | | 28% | | | | | | 997.0 | | | | | | 28% | | | | | | 146.2 | | | | | | 15% | | |

Dropped from FY2024

| Total Revenue | | | | | | $ | 4,033.0 | | | | | 100% | | | | | | $ | 3,622.3 | | | | | 100% | | | | | | $ | 410.7 | | | | | 11% | | |

Dropped from FY2024

| Selling, general and administrative expense | | | | | | Selling, general and administrative expense increased primarily due to $33.5 million in advertising and marketing costs, $30.7 million in compensation and related costs due to higher headcount, $18.0 million in software and data costs, and $10.1 million in travel related expenses. | | |

Dropped from FY2024

We will be exposed to additional foreign currency exchange risk related to our international operations as we expand our manufacturing internationally and as our business continues to increase in international markets.

Dropped from FY2024

We used $282.6 million of the net proceeds from the offering of the 2025 Notes to repurchase a portion of our senior convertible notes due in 2022.

Dropped from FY2024

As of December 31, 2024, we have outstanding senior convertible notes classified as long-term that will mature in May 2028.

Dropped from FY2024

Although the 2025 Notes and 2028 Notes mature in November 2025 and May 2028, respectively, they may be converted into cash and/or shares of our common stock prior to maturity if certain conditions are met.

Dropped from FY2024

See Note 5 “*Debt*” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information about the terms of the Amended Credit Agreement, our senior convertible notes, and the 2028 Capped Calls.

Dropped from FY2024

See the consolidated financial statements in Part II, Item 8 of this Annual Report for the complete consolidated statements of cash flows for these periods.

Dropped from FY2024

![9538](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231_g5.jpg)

Dropped from FY2024

The primary cash flows during the twelve months ended December 31, 2024 and 2023 are described below.

Dropped from FY2024

See the consolidated financial statements in Part II, Item 8 of this Annual Report for complete consolidated statements of cash flows for these periods.

Dropped from FY2024

| | | | | | | | | | December 31, 2024 | | | | | | | | | December 31, 2023 | | |

Dropped from FY2024

| Operating Cash Flows | | | | | | + | | | $576.2 million of net income and $304.5 million of net non-cash adjustments, and a net increase of $108.8 million in changes of working capital balances | | | | | | + | | | $541.5 million of net income and $203.8 million of net non-cash adjustments, and a net increase of $3.2 million in changes of working capital balances | | |

Dropped from FY2024

| Net non-cash adjustments were primarily related to share-based compensation and depreciation and amortization. | | | Net non-cash adjustments were primarily related to share-based compensation and depreciation and amortization. | | | | | | | | | | | | | | | | | |

Dropped from FY2024

| \- | | | $358.8 million in capital expenditures | | | \- | | | $236.6 million in capital expenditures | | | | | | | | | | | |

Dropped from FY2024

| Financing Cash Flows | | | | | | + | | | $28.2 million in proceeds from issuance of common stock under our employee stock plans | | | | | | + | | | $1.23 billion in proceeds from issuance of senior convertible notes, net of issuance costs | | |

Dropped from FY2024

| \- | | | $750.0 million in purchases of treasury stock | | | + | | | $26.6 million in proceeds from issuance of common stock under our employee stock plans | | | | | | | | | | | |

Dropped from FY2024

| | | | | | | \- | | | $787.3 million in payments for conversions of senior convertible notes | | | | | | | | | | | |

Dropped from FY2024

| | | | | | | \- | | | $688.7 million in purchases of treasury stock | | | | | | | | | | | |

Dropped from FY2024

| | | | | | | \- | | | $101.3 million in purchases of capped call transactions | | | | | | | | | | | |

An excerpt. Shown here: 40 of 68 rewritten, all 27 added and all 31 removed. The counts are complete. For every sentence, read Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS in the FY2025 filing and the FY2024 filing.

Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

5 rewritten, 1 added, 1 removed, 19 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

See Note [removed: 5] [added: 4] “*Debt*” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.

Rewritten

We also record exchange rate fluctuations resulting from the translation of the short-term intercompany balances between domestic entities and our international subsidiaries as foreign currency transaction gains or losses and include them in other [removed: income (expense),] [added: income,] net in our consolidated statements of operations.

Rewritten

These forward contracts are not designated as hedging instruments and generally mature in one [removed: month.][added: to six months.]

Rewritten

The derivative gains and losses are included in other [removed: income (expense),] [added: income,] net in our consolidated statements of operations.

Rewritten

See Note [removed: 3] [added: 2] “*Fair Value Measurements*” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.

New in FY2025

As we continue to expand our manufacturing sites in Ireland and Malaysia, we will be subject to additional foreign exchange currency risk.

Dropped from FY2024

We are exposed to additional foreign currency exchange risk related to our foreign operations as we are now manufacturing internationally and as our business continues to increase in markets outside of the United States.

Item 1. BUSINESS

90 rewritten, 74 added, 76 removed, 443 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

We launched our latest generation systems, the Dexcom [removed: G6 integrated] [added: G7] Continuous Glucose Monitoring System, or [removed: G6,] [added: G7,] in [removed: 2018,] [added: 2023,] and [removed: we launched] the Dexcom [removed: G7,] [added: G7 15 Day Continuous Glucose Monitoring System,] or [removed: G7,] [added: G7 15 Day,] in [removed: 2023.][added: late 2025.]

Rewritten

In August 2024, we launched Stelo, our [removed: new] biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.

Rewritten

*Dexcom [removed: G7*][added: ONE+*]

Rewritten

Like the [removed: G6,] [added: G7,] the G7 [added: 15 Day] is an [removed: integrated continuous glucose monitoring system, or iCGM, and is] [added: iCGM] classified as a Class II device by the FDA, and is subject to [added: iCGM] special controls.

Rewritten

The glucose value algorithm, ability to communicate with approved display and mobile devices, and compatibility with Dexcom Clarity, our cloud-based reporting software, are all substantially equivalent in technical performance and capability to the [added: prior generation Dexcom G6 Continuous Glucose Monitoring Integrated System, or] G6.

Rewritten

[removed: Dexcom] [added: The] G7 is cleared in the United States for all people with diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution.

Rewritten

With an overall Mean Absolute Relative Difference, or MARD, of [removed: 8.2%,] [added: 8.0%,] as well as [removed: 94.1%] [added: 94.2%] of values within 20% of their comparator, [removed: Dexcom] [added: the] G7 [added: 15 Day] is the most accurate CGM cleared by the FDA and is clinically proven to lower A1C (a blood test that provides information about average levels of blood glucose, over the prior three months), reduce hyper- and hypoglycemia, and increase time in range.

Rewritten

The G7 [removed: carries] [added: and G7 15 Day carry] forward important features of prior generation Dexcom CGM systems:

Rewritten

The G7 [added: and G7 15 Day] also [removed: has] [added: have] a number of new or improved features compared to our prior generation devices:

Rewritten

- Faster warm up. 30-minute sensor warm [removed: up,] [added: up for the G7,] fastest of any CGM on the [removed: market.][added: market, and 60-minute sensor warm up for the G7 15 Day.]

Rewritten

- New indications for use. [removed: Indicated] [added: For the G7, indicated] in the United States for wear on the back of the upper arm for ages 2 years and older or the upper buttocks for ages 2-6 years old.

Rewritten

Other than the foregoing, the G7 [removed: is] [added: and the G7 15 Day are] generally consistent with our prior generation CGM systems in its technical capabilities and its indications.

Rewritten

Since the G7 [removed: is] [added: and G7 15 Day are] classified by the FDA as a Class II device, [removed: it is subject to] special controls and modifications of, or revisions to, the device may be made under the 510(k) process.

Rewritten

[removed: Along with this classification,] [added: The G7 is an integrated continuous glucose monitoring system, or iCGM, and is classified as a Class II device by] the [removed: FDA established criteria, called] [added: FDA, and is subject to] special [removed: controls, which] [added: controls for iCGMs that] outline requirements for assuring CGM accuracy, reliability and clinical relevance, and which also [removed: describe] [added: outlines] the type of studies and data required to demonstrate acceptable CGM performance.

Rewritten

[removed: Other than the foregoing, the features of] [added: The G7 15 Day extends] the [removed: G6 are] [added: wear period to 15.5 days and is] generally consistent with our prior generation CGM systems in its technical capabilities and its indications.

Rewritten

In [removed: July 2021,] [added: November 2023,] we obtained CE Mark approval for our Dexcom [removed: ONE] [added: ONE+] CGM system, or Dexcom [removed: ONE,] [added: ONE+,] which we have launched in several countries in Europe.

Rewritten

Dexcom [removed: ONE] [added: ONE+] carries many of the same features as the [removed: G6,] [added: G7,] and is indicated for persons, including pregnant women, ages 2 years and older.

Rewritten

Like our other CGM systems, Dexcom [removed: ONE] [added: ONE+] is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Rewritten

In August 2024, we launched Stelo, our [removed: new] biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S. [added: By virtue of not requiring a prescription, Stelo expands access to CGM beyond people with diabetes to include those seeking to optimize metabolic health to more effectively and conveniently manage their glucose levels.]

Rewritten

*Dexcom [removed: Share*][added: Share and Dexcom Follow*]

Rewritten

The Dexcom Share remote monitoring system, offered for use with any current Dexcom system, uses an app on the patient’s compatible iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose [removed: information to the cloud and then to apps on the mobile devices of up to ten designated recipients, or “followers,” who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have a wireless connection.]

Rewritten

The International Diabetes Federation, or IDF, estimates that in [removed: 2021, 537] [added: 2024, 589] million adults (aged 20-79) around the world had diabetes.

Rewritten

IDF estimates that by [removed: 2045,] [added: 2050,] the worldwide incidence of people suffering from diabetes will reach [removed: 783] [added: 853] million.

Rewritten

We estimate that [removed: between 5.0 and 6.0] [added: greater than 6] million people with Type 2 diabetes in the United States must use insulin to manage their diabetes.

Rewritten

![Investor Presentation Glucose [removed: Chart.jpg](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231_g2.jpg)][added: Chart.jpg](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231_g2.jpg)]

Rewritten

- Potential for Improved Outcomes. Randomized clinical trials and peer reviewed published data have demonstrated that patients with diabetes who used [removed: continuous glucose monitoring devices] [added: CGMs] to help manage their disease experienced significant improvements in glucose control, including when compared to patients relying solely on single-point finger stick measurements (i.e., less time in hypoglycemia and hyperglycemia) and reductions in [removed: A1c] [added: A1C] levels when compared to baseline.

Rewritten

Also, our Share [added: and Follow] remote monitoring systems enable users of our current CGM systems to have their sensor glucose information remotely monitored by their family, friends or other designated recipient, or follower, by wirelessly transmitting data from the user’s smart phone to the cloud and then to the follower’s mobile device.

Rewritten

With our [removed: G6] [added: G7] and G7 [added: 15 Day] systems, the functionalities of our proprietary receiver can be obtained through the use of a compatible mobile device, such as an iOS or Android device, and our mobile applications, depending on the patient’s geographic location.

Rewritten

In selling our current CGM systems, we compete directly with the Diabetes Care division of Abbott Laboratories; Medtronic plc’s Diabetes [removed: Group;] [added: Group (which implemented a spinoff of its diabetes business into a separate company called MiniMed);] Roche Diabetes Care, a division of Roche Diagnostics; privately-held LifeScan, Inc.; [removed: and] Ascensia Diabetes [removed: Care,] [added: Care; and other smaller market entrants,] each of which manufactures and markets products for the single-point finger stick device market.

Rewritten

Medtronic [added: (MiniMed)] markets and sells a standalone glucose monitoring product called Guardian Connect, both internationally and in the United States, and a disposable CGM system called Simplera in [added: the U.S. and] international markets.

Rewritten

Medtronic [added: (MiniMed)] and other third parties have developed or are developing, insulin pumps integrated with [removed: continuous glucose monitoring] [added: CGM] systems that provide, among other things, the ability to suspend insulin administration while the user’s glucose levels are low and to automate basal or bolus insulin dosing.

Rewritten

We anticipate that the new facility [added: in Ireland] will add substantial manufacturing capacity.

Rewritten

There are technical challenges to increasing manufacturing capacity, [added: including] finding or enhancing new manufacturing facilities capable of meeting regulatory requirements, government licensure of manufacturing facilities, equipment design and automation, material procurement, problems with production yields, and quality control and assurance.

Rewritten

Additionally, the production of our [removed: continuous glucose monitoring] [added: CGM] systems must occur in a highly controlled and clean environment to minimize particles and other yield-limiting and quality-limiting contaminants.

Rewritten

As of December 31, [removed: 2024,] [added: 2025,] those single sources include [added: but are not limited to] suppliers of application-specific integrated circuits used in our transmitters, seals used for the applicator and certain polymers used to synthesize polymeric membranes for our sensors.

Rewritten

Medicare covers the CGM system, which includes [added: both the receiver device and the] supplies necessary for the use of the device, under the Durable Medical Equipment, or DME, benefit category.

Rewritten

The Local Coverage Determination, or LCD, that [removed: the Centers for Medicare & Medicaid Services (CMS)] [added: CMS] released in April 2023 [removed: extends] [added: extended] Medicare CGM coverage to all patients using insulin.

Rewritten

We also have coverage under certain international markets and Medicaid coverage in approximately [removed: 47 states.][added: 48 states as of December 31, 2025.]

Rewritten

As of December 31, [removed: 2024,] [added: 2025,] the eight largest private third-party payors in the United States, in terms of the number of covered lives, have issued coverage policies for the category of [removed: continuous glucose monitoring] [added: CGM] devices.

Rewritten

U.S. patents, as well as most foreign patents, are generally effective for 20 years from the date the earliest application [added: was filed.]

New in FY2025

*Dexcom G7 and G7 15 Day*

New in FY2025

In April 2025, we obtained marketing authorization from the FDA for the G7 15 Day via the 510(k) review process for people over the age of 18 with diabetes in the United States.

New in FY2025

G7 15 Day will also be covered for Medicare beneficiaries and has met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Services, or CMS.

New in FY2025

- Extended 15.5 day disposable sensor and 10-day disposable sensor, for the G7 15 Day and G7, respectively.

New in FY2025

We anticipate transitioning our G6 customers to our G7 and G7 15 Day sensor systems by the end of 2026.

New in FY2025

Our previous generation Dexcom ONE CGM system, with similar features as G6, is anticipated to be phased out by the end of 2026.

New in FY2025

information to the cloud and then to apps on the mobile devices of up to ten designated recipients, or “followers,” who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have a wireless connection via the Dexcom Follow app.

New in FY2025

Such competitors may benefit from guidance issued on January 6, 2026 by the FDA’s Center for Devices and Radiological Health that effectively broadens the range of products that may be considered “general wellness devices,” including wearables that provide readings around bodily functions and vital signs such as heart rate, blood pressure, and blood glucose.

New in FY2025

We primarily manufacture our products at our manufacturing facilities in Mesa, Arizona and Penang, Malaysia.

New in FY2025

For example, in March 2025, we received an FDA warning letter following inspections of our facilities in San Diego, California, and Mesa, Arizona relating to observed non-conformities in manufacturing

New in FY2025

processes and our quality management system.

New in FY2025

See the section of the Risk Factors entitled “*Risks Related to Manufacturing, Commercial Operations and Commercialization*” and “*If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.*”

New in FY2025

In late 2025, CMS extended the Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) competitive bidding program to include our CGMs and receivers beginning with contracting in 2027, and payment changes effective January 1, 2028.

New in FY2025

Under the program, DMEPOS suppliers compete to become Medicare contract suppliers by submitting bids to furnish certain items.

New in FY2025

CMS anticipates that ten (10) contracts will be awarded for CGMs.

New in FY2025

However, while the competitive bidding program previously used competitive bidding areas, or CBAs, for contract awards, CMS determined that for CGMs and certain other DME, a Remote Item Delivery, or RID, CBA was more appropriate.

New in FY2025

It remains to be seen whether CGMs will be covered under a single, nationwide RID CBA or whether regional RID CBAs will be established.

New in FY2025

In any event, the bid process is expected to result in lower Medicare reimbursement for CGM systems, particularly because CMS is changing the pricing under the RID CBA by setting a single payment amount for covered items at the 75th percentile of the winning bids, rather than using the maximum winning bid.

New in FY2025

Further, CMS has reclassified CGMs and insulin infusion pumps to items that require frequent and substantial servicing and will phase in monthly rental payments for these items.

New in FY2025

CMS will bundle the rental amount for the receiver device with payment for the supplies and accessories in the new payment amount.

New in FY2025

Beneficiaries who own their CGMs or insulin infusion pumps may either continue to use them until replacement is necessary or immediately switch to a rental item.

New in FY2025

The bid limit will be monthly fee schedule amounts for the supplies plus the average purchase fee schedule amounts for the CGM receiver device divided by 60 (intended to capture the 5-year useful life of the device).

New in FY2025

As a result, we expect that Medicare reimbursement for our CGM systems will decrease beginning in 2028.

New in FY2025

CMS is required by law to recompete these contracts at least once every three years and to roll out the competitive bidding process nationally or adjust prices in non-competitive bidding areas to match competitive bidding prices.

New in FY2025

The implementation of the competitive bidding program may result in reduced Medicare payment for CGMs in both competitive bidding areas and non-competitive bidding areas.

New in FY2025

Our Board of Directors has delegated responsibility to our Nominating and Governance Committee for the oversight of sustainability matters.

New in FY2025

Additionally, the Corporate Sustainability Steering Committee, consisting of members of senior management from Legal, Finance, Human Resources, Commercial and Operations, is responsible for establishing programs, policies and practices relating to sustainability matters, under the auspice of the Nominating and Governance Committee.

New in FY2025

The QMSR amends the quality regulations to align more closely with international consensus standards for quality management systems for medical devices used by other regulatory authorities around the world.

New in FY2025

Some devices are placed in Class III, which requires approval of a PMA application and may require human clinical trials, if they are deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or certain implantable devices,

New in FY2025

In March 2025, we received an FDA warning letter following inspections of our facilities in San Diego, California, and Mesa, Arizona.

New in FY2025

In the warning letter, the FDA cited deficiencies in the response letters sent by us to the FDA following the Form 483, List of Investigational Observations that was delivered to us in connection with the inspection of our San Diego, California facility that occurred from October 2024 through November 2024, and the inspection of our Mesa, Arizona facility that occurred in June 2024.

New in FY2025

The warning letter describes observed non-conformities in manufacturing processes and our quality management system.

New in FY2025

We take the matters identified in the warning letter seriously and have submitted responses to the Form 483 and to the FDA warning letter.

New in FY2025

While the warning letter does not restrict our ability to produce, market, manufacture or distribute products, require recall of any products, nor restrict our ability to seek FDA 510(k) clearance of new products, we may fail to satisfy these regulatory requirements to the FDA’s satisfaction, and any failure to do so could result in the foregoing occurring.

New in FY2025

See the risk factor entitled “*If we or our suppliers or distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market*.”

New in FY2025

payments, and providing anything at less than its fair market value.

New in FY2025

Sanctions for violations of the CMPL

New in FY2025

We are not a “provider, practitioner or supplier” to which the Beneficiary Inducement CMP applies as we do not directly bill Medicare; therefore, our liability under the Beneficiary Inducement CMP is materially reduced.

New in FY2025

information.

New in FY2025

These laws include, for example, the California Consumer Privacy Act, or CCPA, which came into effect January 1, 2020 and was amended and expanded by the California Privacy Rights Act, or CPRA, which came into effect on January 1, 2023, and similar state laws.

Dropped from FY2024

- Finger stick elimination. No finger sticks are needed for calibration or diabetes treatment decisions, consistent with the instructions for use, unless symptoms do not match readings.

Dropped from FY2024

- Continuous glucose readings. Automatically sends glucose readings to a Dexcom receiver or compatible display device every five minutes.

Dropped from FY2024

- Mobile app and sharing. Compatibility with mobile device applications allows for sharing glucose information with up to 10 other people for added support and care coordination.

Dropped from FY2024

- Customizable alarms and alerts. Personalized alert schedule immediately warns the user of pending dangerous high and low blood sugar levels.

Dropped from FY2024

- Easy sensor application. Complete redesign of the sensor applicator allows for one-touch, simple self-insertion.

Dropped from FY2024

- Predictive low alert. Alert feature intended to predict hypoglycemia before it hits to help avoid dangerous low blood sugar events.

Dropped from FY2024

- Extended 10-day disposable sensor.

Dropped from FY2024

G6 and substantially equivalent devices of this generic type that may later receive marketing authorization are referred to as integrated continuous glucose monitoring systems, or iCGMs, and have been classified as Class II devices by the FDA.

Dropped from FY2024

The G6 is designed to automatically transfer data from the transmitter to the Dexcom receiver device as well as allow our transmitter to run an algorithm to generate a glucose value and to communicate directly to a patient’s compatible mobile device, including iPhone®, iPod touch®, iPad®, and certain Android® mobile devices.

Dropped from FY2024

A patient’s glucose data can also be displayed on wearable devices, like the Apple Watch® and Wear OS by Google devices.

Dropped from FY2024

The G6 transmitter has a labeled useful life of three months.

Dropped from FY2024

Data from the G6 can be integrated with Dexcom Clarity, our cloud-based reporting software, for personalized, easy-to-understand analysis of trends that may improve diabetes management.

Dropped from FY2024

In the United States, the G6 is covered by Medicare and Medicaid in the majority of states and by commercial insurers, subject to satisfaction of certain eligibility and coverage criteria for individuals with both Type 1 and Type 2 diabetes.

Dropped from FY2024

In October 2019, we also received marketing authorization from the FDA for the Dexcom G6 Pro, or G6 Pro, which allows healthcare professionals to purchase the G6 for use by their patients.

Dropped from FY2024

The G6 Pro has many of same features as the G6 and is intended for healthcare professionals to use with their patients ages two years and up.

Dropped from FY2024

The G6 Pro may be used in a blinded or unblinded mode for up to 10 days.

Dropped from FY2024

For the G6, the sensor is inserted by the user and is intended to be used continuously for up to 10 days, after which it may be replaced with a new disposable sensor.

Dropped from FY2024

Our transmitter is reusable until it reaches the end of its use life, labeled as three months.

Dropped from FY2024

Our receiver is also reusable.

Dropped from FY2024

As we continue to establish an installed base of customers using our products, we expect to generate an increasing portion of our revenues through recurring sales of our disposable sensors.

Dropped from FY2024

The G6 carries forward important features of prior generation Dexcom CGM systems:

Dropped from FY2024

- Integration with the world’s largest connected CGM ecosystem (including Apple Watch, Garmin and other digital health apps).

Dropped from FY2024

The G6 also has a number of new or improved features compared to our prior generation devices:

Dropped from FY2024

- Discreet and low profile. A redesigned transmitter with a 28% lower profile than the previous generation Dexcom CGM system makes the device comfortable and easy to wear under clothing.

Dropped from FY2024

- Medication blocking. Allows for more accurate glucose readings without interference from common medications taken at typical indication doses, such as acetaminophen.

Dropped from FY2024

- Extended 10-day disposable sensor. Up to 10-day sensor use allows for 43% longer wear than previous generation Dexcom CGM systems.

Dropped from FY2024

Since the G6 is classified by the FDA as a Class II device, it is subject to special controls and modifications of, or revisions to, the device may be made under the 510(k) process.

Dropped from FY2024

*Dexcom ONE*

Dropped from FY2024

Dexcom ONE consists of three main components: a sensor, a transmitter, and a display device consisting of either the Dexcom ONE app for users with a compatible mobile device, or a Dexcom ONE receiver.

Dropped from FY2024

In November 2023, we obtained CE Mark approval for Dexcom ONE+.

Dropped from FY2024

This updated version of our Dexcom ONE system builds upon the software experience of Dexcom ONE with certain additional features, while allowing customers to adopt the all-in-one wearable technology of our G7 CGM system.

Dropped from FY2024

*Verily Collaboration*

Dropped from FY2024

Our Restated Collaboration Agreement with Verily Life Science LLC (an Alphabet Company) and Verily Ireland Limited (collectively, Verily) provides us with an exclusive license to use intellectual property of Verily resulting from the collaboration, and certain Verily patents, in the development, manufacture and commercialization of blood-based or interstitial glucose monitoring products more generally (subject to certain exclusions, which are outside of the CGM field as it is commonly understood).

Dropped from FY2024

It also provides us with non-exclusive license rights under Verily’s other intellectual property rights to develop, manufacture, and commercialize those kinds of glucose monitoring products and certain CGM product companion software functionalities.

Dropped from FY2024

In connection with the Restated Collaboration Agreement, we developed, launched and commercialized a CGM product in connection with the collaboration.

Dropped from FY2024

In consideration of Verily’s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we made upfront, incentive, and the product regulatory approval payments, and payments for contingent sales-based milestones upon the achievement of certain revenue targets.

Dropped from FY2024

See Note 2 “*Development and Other Agreements*” to the consolidated financial statements in Part II, Item 8 of this Annual Report and Exhibit 10.13 of this Annual Report on Form 10-K for a further description of the Restated Collaboration Agreement, including the number of shares of stock for milestone payments.

Dropped from FY2024

Of the $413 billion in overall expenses, the ADA estimated that approximately $307 billion were direct costs associated with diabetes care, chronic complications and excess general medical costs, and $106 billion were indirect costs.

Dropped from FY2024

The ADA also found that in 2022, average medical expenditures among people with diagnosed diabetes were 2.6 times higher than for people without diabetes.

Dropped from FY2024

According to the IDF, 2021 expenditures attributable to diabetes were estimated to be $966 billion globally, an increase of 27% from their previous estimate in 2019.

An excerpt. Shown here: 40 of 90 rewritten, 40 of 74 added and 40 of 76 removed. The counts are complete. For every sentence, read Item 1. BUSINESS in the FY2025 filing and the FY2024 filing.

Item 3. LEGAL PROCEEDINGS

7 rewritten, 40 added, 46 removed, 8 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

[removed: Securities] [added: G6 and G7] Class Action Litigation

Rewritten

On December 13, 2024, the court appointed lead plaintiff [removed: court] and consolidated the three actions (now captioned In [removed: Re:] [added: re] Dexcom, Inc. Class Action Securities Litigation, Lead Case No.: 24-cv-1485-RSH-VET).

Rewritten

The consolidated complaint alleges violations of the [removed: Securities] Exchange Act against us and certain of our current and former executive officers for allegedly making false and misleading statements between April 28, 2023 and July 25, 2024, with respect to our expected revenue for fiscal 2024 and ability to capitalize on our growth potential.

Rewritten

Our deadline to respond to the [removed: consolidated] complaint [added: in *Dickinson* currently] is March [removed: 13, 2025.][added: 23, 2026.]

Rewritten

Between September 13 and [removed: October 16, 2024, two] [added: April 14, 2025, three] putative stockholders filed derivative lawsuits against us and certain of our current and former executive officers and directors in the United States District Court for the Southern District of California.

Rewritten

The derivative complaints allege factual allegations largely tracking allegations made in the [added: In re Dexcom, Inc.] Securities Class Action Litigation and seek, among other things, damages and restitution to be paid to the Company by the individual defendants, punitive damages, and attorney’s fees and costs.

Rewritten

[removed: On December 16, 2024, the court issued an order (i) consolidating the derivative actions, (ii) appointing lead counsel in the] [added: These actions have been] consolidated [removed: action] (captioned In Re: Dexcom, Inc. Stockholder Derivative Litigation, Lead Case No.: 24-cv-1645-RSH-VET), and [removed: (iii) staying the consolidated action until the court’s] [added: are currently stayed pending a] resolution of [removed: any motions] [added: the anticipated motion] to dismiss in the [added: In re Dexcom, Inc.] Securities Class Action Litigation.

New in FY2025

Securities Class Actions

New in FY2025

On March 13, 2025, we filed a motion to dismiss the consolidated complaint.

New in FY2025

On May 14, 2025, the court granted the motion to dismiss with leave to amend.

New in FY2025

On May 28, 2025, lead plaintiff filed an amended consolidated complaint.

New in FY2025

On June 11, 2025, we filed a motion to dismiss the amended consolidated complaint.

New in FY2025

On September 9, 2025, the court granted in part and denied in part the motion to dismiss.

New in FY2025

On October 7, 2025, defendants answered the amended consolidated complaint.

New in FY2025

On October 10, 2025, defendants filed a motion for judgment on the pleadings as to the two surviving challenged statements.

New in FY2025

On January 7, 2026, the court granted defendants’ motion for judgment on the pleadings with leave to amend.

New in FY2025

On February 6, 2026, lead plaintiff filed a second amended consolidated complaint.

New in FY2025

Defendants’ deadline to respond to the second amended consolidated complaint is February 20, 2026.

New in FY2025

On October 27, 2025, a putative class action complaint was filed against us and certain of our executive officers in the United States District Court for the Southern District of New York (captioned Prime v.

New in FY2025

Dexcom, Inc., et al, Case No.: 1:25-cv-08912).

New in FY2025

The complaint alleges violations of the Exchange Act against us and certain of our executive officers for allegedly making false and misleading statements between July 26, 2024 and September 17, 2025, with respect to the accuracy, reliability, and functionality of our G7 device, as well as our enhancements to and manufacturing of the device.

New in FY2025

A lead plaintiff has been appointed and must file an amended complaint no later than April 10, 2026.

New in FY2025

Our deadline to respond to the amended complaint is June 9, 2026.

New in FY2025

On September 25, 2025, an additional derivative lawsuit was filed against us and certain of our current and former executive officers and directors in the Court of Chancery of the State of Delaware.

New in FY2025

The allegations largely track those made in the In re Dexcom, Inc. Securities Class Action Litigation and seek, among other things, damages and restitution to be paid to the Company by the individual defendants, punitive damages, and attorney’s fees and costs.

New in FY2025

This action This action is currently stayed pending a resolution of the anticipated motion to dismiss in the In re Dexcom, Inc. Securities Class Action Litigation.

New in FY2025

Between September 29, 2025, and January 8, 2026, various plaintiffs, purported users of G6 or G7 devices, filed six overlapping putative class action complaints against us.

New in FY2025

Four of the complaints originally were filed and are pending in the United States District Court for the Southern District of California (Levens, et al.

New in FY2025

v.

New in FY2025

Dexcom, Inc., No. 3:25-cv-02565-BJC-BLM; Estravit v.

New in FY2025

Dexcom, Inc., No. 3:25-cv-02845-BJC-BLM; and Dalora v.

New in FY2025

Dexcom, Inc., No. 3:25-cv-03210-BJC-BLM; *Dickinson, et al.

New in FY2025

v.

New in FY2025

Dexcom, Inc.* Dickinson, et al.

New in FY2025

v.

New in FY2025

Dexcom, Inc., No. 3:26-cv-00102-BJC-BLM); one of the complaints originally was filed in United States District Court for the Central District of California, and subsequently transferred to the United States District Court for the Southern District of California (Grisoli, et al.

New in FY2025

v.

New in FY2025

Dexcom, Inc., No. 3:25-cv-03488-BJC-BLM); and one of the complaints was filed and is pending in the Superior Court of Los Angeles County, California (Chatelain v.

New in FY2025

Dexcom, Inc., No. 25STCV30722).

New in FY2025

Plaintiffs in all six actions allege they overpaid for G6 and/or G7 devices or components that were worth less than the purchase price because, among other reasons, G6 and/or G7 devices or components they purchased allegedly were adulterated or misbranded under federal law; G6 and/or G7 devices or components they purchased allegedly failed to perform as advertised; and because we allegedly misled patients and providers about the safety, accuracy, efficacy, and reliability of G6 and/or G7 devices or components.

New in FY2025

Plaintiffs in each action assert various state law consumer protection, express and implied warranty, common law, and Magnuson-Moss Warranty Act claims, and seek, among other things, damages for economic losses, restitution, disgorgement, injunctive relief, and attorneys’ fees and costs.

New in FY2025

Plaintiffs seek to represent nationwide classes and state-specific subclasses of individuals.

New in FY2025

The five cases in the United States District Court for the Southern District of California have been deemed related cases and have been assigned to a single judge.

New in FY2025

On December 30, 2025, and January 5, 2026, plaintiffs filed motions to consolidate the four federal court cases, to appoint interim class counsel, and to establish a briefing schedule on competing motions to appoint interim class counsel.

New in FY2025

The Court has stayed all deadlines to respond to the complaints in four of the federal court actions (*Levens*, *Estravit*, *Dalora*, and *Grisoli*) pending the filing of a consolidated complaint.

New in FY2025

In the putative class action pending in Los Angeles County Superior Court, our initial status conference is scheduled for February 23, 2026.

New in FY2025

The case is stayed until at least the February 23, 2026, status conference.

Dropped from FY2024

Litigation and Settlement with Abbott

Dropped from FY2024

From June 2021 through December 2024, we and certain Abbott Diabetes Care, Inc. (“Abbott”) entities served patent infringement complaints against each other in multiple jurisdictions against certain continuous glucose monitoring products of each company.

Dropped from FY2024

In June 2021, we initiated patent infringement litigation against Abbott in the United States (U.S.D.C., Western District of Texas) and Germany (National Court (“N.C.”) in Mannheim).

Dropped from FY2024

In May 2023, we filed additional patent infringement actions in Germany (N.C. in Munich).

Dropped from FY2024

In July and August 2023, we initiated patent infringement litigation in the United Patent Court (“UPC”) (Paris & Munich) and in Spain (Commercial Courts of Barcelona).

Dropped from FY2024

In October and November 2023, we initiated patent infringement litigation in Germany (N.C. in Munich) and in the UPC (Paris & Munich).

Dropped from FY2024

In January 2024, we initiated patent infringement litigation in Germany (N.C. in Hamburg).

Dropped from FY2024

In July 2021, one day after we initiated litigation in the U.S.D.C., Western District of Texas, Abbott initiated patent infringement litigation against Dexcom in the United States (U.S.D.C., Delaware (“D1”)).

Dropped from FY2024

Shortly thereafter, Abbott filed additional patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales) and Germany (N.C. in Mannheim and Dusseldorf).

Dropped from FY2024

In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in the Business and Property Courts of England and Wales.

Dropped from FY2024

Three trials on liability were conducted in the United Kingdom.

Dropped from FY2024

On October 18, 2023 and June 28, 2024, judgment was handed down in favor of Dexcom, finding the Abbott patents to be invalid and not infringed.

Dropped from FY2024

On January 15, 2024, judgment was handed down invalidating both Abbott and Dexcom’s patents.

Dropped from FY2024

In December 2021, Abbott filed a breach of contract lawsuit against Dexcom in the United States (U.S.D.C., District of Delaware) alleging that Dexcom breached the parties’ Settlement and License Agreement dated July 2, 2014 (“SLA”).

Dropped from FY2024

The U.S.D.C., District of Delaware consolidated Abbott’s breach of contract lawsuit with Dexcom’s patent infringement lawsuit which had been transferred from the U.S.D.C., Western District of Texas (“D3”).

Dropped from FY2024

Dexcom asserted counterclaims that Abbott also breached the SLA.

Dropped from FY2024

A jury trial on Abbott’s breach of contract claims commenced on July 10, 2023.

Dropped from FY2024

On July 14, 2023, the jury verdict determined that Abbott was not licensed to thirteen claims of certain Dexcom patents and that Abbott was licensed to five claims.

Dropped from FY2024

In April 2022, Abbott initiated the inter partes review (“IPR”) process on the asserted claims of Dexcom’s patents in D3.

Dropped from FY2024

The U.S. Patent and Trademark Office (the “PTO”) denied institution of one of Dexcom’s patents and instituted IPR on the other four.

Dropped from FY2024

Ultimately, in November 2023, the PTO issued its Final Written Decision, upholding claims of two Dexcom patents to be patentable, which cover factory calibration and certain alarms and alerts, and two to be unpatentable, which cover certain sensor code and sensor configurations.

Dropped from FY2024

In February 2023, Abbott filed patent infringement litigation against us in Germany (N.C. in Hamburg and Munich).

Dropped from FY2024

In March 2023, Abbott filed a patent infringement litigation in the United States (U.S.D.C., Delaware (“D4”)) and we filed counterclaims for patent infringement in that action in June 2023.

Dropped from FY2024

In June 2023, Abbott filed patent infringement litigation actions in the United Kingdom (Business and Property Courts of England and Wales).

Dropped from FY2024

In response to the lawsuits initiated by Abbott in the United Kingdom, Dexcom also filed patent infringement counterclaims in that jurisdiction.

Dropped from FY2024

Abbott’s patent infringement trial, “D1”, against Dexcom commenced in the U.S.D.C., District of Delaware in March 2024.

Dropped from FY2024

In the lead up to trial, the U.S.D.C., District of Delaware invalidated one of Abbott’s patents on factory calibration and Abbott dropped four other patents from the litigation.

Dropped from FY2024

The claims litigated were isolated to the inserter mechanism and the wearable seal and mount of Dexcom’s G6.

Dropped from FY2024

On March 22, 2024, a jury returned a mixed verdict.

Dropped from FY2024

The jury found that Dexcom infringes one patent, that Dexcom did not infringe a second patent, and that Dexcom also did not infringe a third patent, which the jury also found invalid.

Dropped from FY2024

The jury found that any infringement was not willful.

Dropped from FY2024

It could not reach unanimity as to a fourth patent.

Dropped from FY2024

No determination of damages was made or awarded.

Dropped from FY2024

Commencing in January 2024, patent infringement hearings between Abbott and Dexcom were scheduled to take place in Germany wherein each sought damages and injunctive relief against the other.

Dropped from FY2024

All but one of Abbott’s offensive hearings were either stayed or cancelled entirely due to parallel invalidity proceedings and nullity decisions.

Dropped from FY2024

After a February 28, 2024 hearing in Munich wherein Abbott asserted patent infringement claims against Dexcom, Dexcom received a favorable non-infringement decision.

Dropped from FY2024

On July 24, 2024, Dexcom received a decision from the Munich court related to the July 3, 2024 hearing, staying our offensive infringement proceedings pending the outcome of an opposition proceeding.

Dropped from FY2024

On July 31, 2024, Dexcom received a decision from the Munich courts related to hearings in April 2024, dismissing our claims for infringement.

Dropped from FY2024

On November 6, 2024, Dexcom received a favorable decision from the Munich District Court, finding Abbott infringes Dexcom’s patent and granting an injunction regarding Abbott’s LibrLinkUp application in Germany.

Dropped from FY2024

Under the Settlement Agreement described below, Abbott obtained a license to such patent and the injunction no longer applies.

An excerpt. Shown here: all 7 rewritten, all 40 added and 40 of 46 removed. The counts are complete. For every sentence, read Item 3. LEGAL PROCEEDINGS in the FY2025 filing and the FY2024 filing.

Cover and table of contents

28 rewritten, 9 added, 9 removed, 103 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

For the fiscal year ended December 31, [removed: 2024][added: 2025]

Rewritten

[removed: ![dexcom-logo-green-rgb.jpg](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231_g1.jpg)][added: ![dexcom-logo-green-rgb.jpg](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231_g1.jpg)]

Rewritten

As of June [removed: 28, 2024,] [added: 30, 2025,] the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately [removed: $45.3] [added: $34.2] billion based on the closing sales price of [removed: $113.38] [added: $87.29] per share as reported on the Nasdaq Global Select Market on that date.

Rewritten

| Class | | | | | | Outstanding at February [removed: 6, 2025] [added: 5, 2026] | | |

Rewritten

| Common stock, $0.001 par value per share | | | | | | [removed: 390,772,018] [added: 384,864,842] | | |

Rewritten

Portions of the registrant’s definitive proxy statement relating to its [removed: 2025] [added: 2026] Annual Meeting of Stockholders (the “Proxy Statement”) are incorporated by reference in Part III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item numbers, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.

Rewritten

| [ITEM [removed: 1.](#i6a987b433ae84cbfb2328647e6586107_25)] [added: 1.](#i863d5bab53004feeb077a051d3498b26_22)] | | | [removed: [Business](#i6a987b433ae84cbfb2328647e6586107_25)] [added: [Business](#i863d5bab53004feeb077a051d3498b26_22)] | | | [removed: [6](#i6a987b433ae84cbfb2328647e6586107_25)] [added: [6](#i863d5bab53004feeb077a051d3498b26_22)] | | |

Rewritten

| [ITEM [removed: 1A.](#i6a987b433ae84cbfb2328647e6586107_64)] [added: 1A.](#i863d5bab53004feeb077a051d3498b26_64)] | | | [Risk [removed: Factors](#i6a987b433ae84cbfb2328647e6586107_64)] [added: Factors](#i863d5bab53004feeb077a051d3498b26_64)] | | | [removed: [27](#i6a987b433ae84cbfb2328647e6586107_64)] [added: [27](#i863d5bab53004feeb077a051d3498b26_64)] | | |

Rewritten

| [ITEM [removed: 1B.](#i6a987b433ae84cbfb2328647e6586107_112)] [added: 1B.](#i863d5bab53004feeb077a051d3498b26_115)] | | | [Unresolved Staff [removed: Comments](#i6a987b433ae84cbfb2328647e6586107_112)] [added: Comments](#i863d5bab53004feeb077a051d3498b26_115)] | | | [removed: [69](#i6a987b433ae84cbfb2328647e6586107_112)] [added: [71](#i863d5bab53004feeb077a051d3498b26_115)] | | |

Rewritten

| [ITEM [removed: 1C.](#i6a987b433ae84cbfb2328647e6586107_115)] [added: 1C.](#i863d5bab53004feeb077a051d3498b26_118)] | | | [removed: [Cybersecurity](#i6a987b433ae84cbfb2328647e6586107_115)] [added: [Cybersecurity](#i863d5bab53004feeb077a051d3498b26_118)] | | | [removed: [69](#i6a987b433ae84cbfb2328647e6586107_115)] [added: [71](#i863d5bab53004feeb077a051d3498b26_118)] | | |

Rewritten

| [ITEM [removed: 3.](#i6a987b433ae84cbfb2328647e6586107_121)] [added: 3.](#i863d5bab53004feeb077a051d3498b26_124)] | | | [Legal [removed: Proceedings](#i6a987b433ae84cbfb2328647e6586107_121)] [added: Proceedings](#i863d5bab53004feeb077a051d3498b26_124)] | | | [removed: [71](#i6a987b433ae84cbfb2328647e6586107_121)] [added: [73](#i863d5bab53004feeb077a051d3498b26_124)] | | |

Rewritten

| [ITEM [removed: 4.](#i6a987b433ae84cbfb2328647e6586107_124)] [added: 4.](#i863d5bab53004feeb077a051d3498b26_130)] | | | [Mine Safety [removed: Disclosures](#i6a987b433ae84cbfb2328647e6586107_124)] [added: Disclosures](#i863d5bab53004feeb077a051d3498b26_130)] | | | [removed: [73](#i6a987b433ae84cbfb2328647e6586107_124)] [added: [74](#i863d5bab53004feeb077a051d3498b26_130)] | | |

Rewritten

| [ITEM [removed: 5.](#i6a987b433ae84cbfb2328647e6586107_130)] [added: 5.](#i863d5bab53004feeb077a051d3498b26_136)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i6a987b433ae84cbfb2328647e6586107_130)] [added: Securities](#i863d5bab53004feeb077a051d3498b26_136)] | | | [removed: [74](#i6a987b433ae84cbfb2328647e6586107_130)] [added: [75](#i863d5bab53004feeb077a051d3498b26_136)] | | |

Rewritten

| [ITEM [removed: 7.](#i6a987b433ae84cbfb2328647e6586107_139)] [added: 7.](#i863d5bab53004feeb077a051d3498b26_148)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i6a987b433ae84cbfb2328647e6586107_139)] [added: Operations](#i863d5bab53004feeb077a051d3498b26_148)] | | | [removed: [76](#i6a987b433ae84cbfb2328647e6586107_139)] [added: [77](#i863d5bab53004feeb077a051d3498b26_148)] | | |

Rewritten

| [ITEM [removed: 7A.](#i6a987b433ae84cbfb2328647e6586107_163)] [added: 7A.](#i863d5bab53004feeb077a051d3498b26_178)] | | | [Quantitative and Qualitative Disclosures about Market [removed: Risk](#i6a987b433ae84cbfb2328647e6586107_163)] [added: Risk](#i863d5bab53004feeb077a051d3498b26_178)] | | | [removed: [87](#i6a987b433ae84cbfb2328647e6586107_163)] [added: [87](#i863d5bab53004feeb077a051d3498b26_178)] | | |

Rewritten

| [ITEM [removed: 8.](#i6a987b433ae84cbfb2328647e6586107_175)] [added: 8.](#i863d5bab53004feeb077a051d3498b26_190)] | | | [Financial Statements and Supplementary [removed: Data](#i6a987b433ae84cbfb2328647e6586107_175)] [added: Data](#i863d5bab53004feeb077a051d3498b26_190)] | | | [removed: [88](#i6a987b433ae84cbfb2328647e6586107_175)] [added: [88](#i863d5bab53004feeb077a051d3498b26_190)] | | |

Rewritten

| [ITEM [removed: 9.](#i6a987b433ae84cbfb2328647e6586107_178)] [added: 9.](#i863d5bab53004feeb077a051d3498b26_193)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i6a987b433ae84cbfb2328647e6586107_178)] [added: Disclosure](#i863d5bab53004feeb077a051d3498b26_193)] | | | [removed: [88](#i6a987b433ae84cbfb2328647e6586107_178)] [added: [88](#i863d5bab53004feeb077a051d3498b26_193)] | | |

Rewritten

| [ITEM [removed: 9A.](#i6a987b433ae84cbfb2328647e6586107_181)] [added: 9A.](#i863d5bab53004feeb077a051d3498b26_196)] | | | [Controls and [removed: Procedures](#i6a987b433ae84cbfb2328647e6586107_181)] [added: Procedures](#i863d5bab53004feeb077a051d3498b26_196)] | | | [removed: [89](#i6a987b433ae84cbfb2328647e6586107_181)] [added: [89](#i863d5bab53004feeb077a051d3498b26_196)] | | |

Rewritten

| [ITEM [removed: 9B.](#i6a987b433ae84cbfb2328647e6586107_187)] [added: 9B.](#i863d5bab53004feeb077a051d3498b26_202)] | | | [Other [removed: Information](#i6a987b433ae84cbfb2328647e6586107_187)] [added: Information](#i863d5bab53004feeb077a051d3498b26_202)] | | | [removed: [91](#i6a987b433ae84cbfb2328647e6586107_187)] [added: [91](#i863d5bab53004feeb077a051d3498b26_202)] | | |

Rewritten

| [ITEM [removed: 9C.](#i6a987b433ae84cbfb2328647e6586107_193)] [added: 9C.](#i863d5bab53004feeb077a051d3498b26_214)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i6a987b433ae84cbfb2328647e6586107_193)] [added: Inspections](#i863d5bab53004feeb077a051d3498b26_214)] | | | [removed: [91](#i6a987b433ae84cbfb2328647e6586107_193)] [added: [91](#i863d5bab53004feeb077a051d3498b26_214)] | | |

Rewritten

| [ITEM [removed: 10.](#i6a987b433ae84cbfb2328647e6586107_199)] [added: 10.](#i863d5bab53004feeb077a051d3498b26_220)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i6a987b433ae84cbfb2328647e6586107_199)] [added: Governance](#i863d5bab53004feeb077a051d3498b26_220)] | | | [removed: [92](#i6a987b433ae84cbfb2328647e6586107_199)] [added: [92](#i863d5bab53004feeb077a051d3498b26_220)] | | |

Rewritten

| [ITEM [removed: 11.](#i6a987b433ae84cbfb2328647e6586107_202)] [added: 11.](#i863d5bab53004feeb077a051d3498b26_223)] | | | [Executive [removed: Compensation](#i6a987b433ae84cbfb2328647e6586107_202)] [added: Compensation](#i863d5bab53004feeb077a051d3498b26_223)] | | | [removed: [92](#i6a987b433ae84cbfb2328647e6586107_202)] [added: [92](#i863d5bab53004feeb077a051d3498b26_223)] | | |

Rewritten

| [ITEM [removed: 12.](#i6a987b433ae84cbfb2328647e6586107_205)] [added: 12.](#i863d5bab53004feeb077a051d3498b26_226)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i6a987b433ae84cbfb2328647e6586107_205)] [added: Matters](#i863d5bab53004feeb077a051d3498b26_226)] | | | [removed: [92](#i6a987b433ae84cbfb2328647e6586107_205)] [added: [92](#i863d5bab53004feeb077a051d3498b26_226)] | | |

Rewritten

| [ITEM [removed: 13.](#i6a987b433ae84cbfb2328647e6586107_208)] [added: 13.](#i863d5bab53004feeb077a051d3498b26_229)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i6a987b433ae84cbfb2328647e6586107_208)] [added: Independence](#i863d5bab53004feeb077a051d3498b26_229)] | | | [removed: [92](#i6a987b433ae84cbfb2328647e6586107_208)] [added: [92](#i863d5bab53004feeb077a051d3498b26_229)] | | |

Rewritten

| [ITEM [removed: 14.](#i6a987b433ae84cbfb2328647e6586107_211)] [added: 14.](#i863d5bab53004feeb077a051d3498b26_232)] | | | [Principal Accountant Fees and [removed: Services](#i6a987b433ae84cbfb2328647e6586107_211)] [added: Services](#i863d5bab53004feeb077a051d3498b26_232)] | | | [removed: [93](#i6a987b433ae84cbfb2328647e6586107_211)] [added: [93](#i863d5bab53004feeb077a051d3498b26_232)] | | |

Rewritten

| [ITEM [removed: 15.](#i6a987b433ae84cbfb2328647e6586107_217)] [added: 15.](#i863d5bab53004feeb077a051d3498b26_238)] | | | [removed: [Exhibits](#i6a987b433ae84cbfb2328647e6586107_217)] [added: [Exhibits](#i863d5bab53004feeb077a051d3498b26_238)] and [Financial Statement [removed: Schedules](#i6a987b433ae84cbfb2328647e6586107_217)] [added: Schedules](#i863d5bab53004feeb077a051d3498b26_238)] | | | [removed: [94](#i6a987b433ae84cbfb2328647e6586107_217)] [added: [94](#i863d5bab53004feeb077a051d3498b26_238)] | | |

Rewritten

| [ITEM [removed: 16.](#i6a987b433ae84cbfb2328647e6586107_220)] [added: 16.](#i863d5bab53004feeb077a051d3498b26_241)] | | | [Form 10-K [removed: Summary](#i6a987b433ae84cbfb2328647e6586107_220)] [added: Summary](#i863d5bab53004feeb077a051d3498b26_241)] | | | [removed: [96](#i6a987b433ae84cbfb2328647e6586107_220)] [added: [96](#i863d5bab53004feeb077a051d3498b26_241)] | | |

Rewritten

Our website address is located at [removed: dexcom.com] [added: www.dexcom.com] and our investor relations website is located at investors.dexcom.com.

New in FY2025

| [PART I](#i863d5bab53004feeb077a051d3498b26_22) | | | | | | | | |

New in FY2025

| [ITEM 2.](#i863d5bab53004feeb077a051d3498b26_121) | | | [Properties](#i863d5bab53004feeb077a051d3498b26_121) | | | [73](#i863d5bab53004feeb077a051d3498b26_121) | | |

New in FY2025

| [PART II](#i863d5bab53004feeb077a051d3498b26_133) | | | | | | | | |

New in FY2025

| [ITEM 6.](#i863d5bab53004feeb077a051d3498b26_145) | | | [\[Reserved\]](#i863d5bab53004feeb077a051d3498b26_145) | | | [76](#i863d5bab53004feeb077a051d3498b26_145) | | |

New in FY2025

| [PART III](#i863d5bab53004feeb077a051d3498b26_217) | | | | | | | | |

New in FY2025

| [PART IV](#i863d5bab53004feeb077a051d3498b26_235) | | | | | | | | |

New in FY2025

| | | | [Signatures](#i863d5bab53004feeb077a051d3498b26_244) | | | [97](#i863d5bab53004feeb077a051d3498b26_244) | | |

New in FY2025

“Dexcom”, “Dexcom Clarity”, “Dexcom Follow”, “Dexcom One”, “Dexcom ONE+” “Dexcom Share”, “Stelo”, and any related logos and design marks appearing in this Annual Report on Form 10-K are either registered trademarks or trademarks of DexCom, Inc. in the United States and/or other countries.

New in FY2025

- If we, our suppliers, or our distributors fail to comply with ongoing regulatory requirements, including responding to the FDA warning letter, or if we have unanticipated problems with our products, the products could be subject to restrictions or withdrawal from the market.

Dropped from FY2024

| [PART I](#i6a987b433ae84cbfb2328647e6586107_25) | | | | | | | | |

Dropped from FY2024

| [ITEM 2.](#i6a987b433ae84cbfb2328647e6586107_118) | | | [Properties](#i6a987b433ae84cbfb2328647e6586107_118) | | | [71](#i6a987b433ae84cbfb2328647e6586107_118) | | |

Dropped from FY2024

| [PART II](#i6a987b433ae84cbfb2328647e6586107_127) | | | | | | | | |

Dropped from FY2024

| [ITEM 6.](#i6a987b433ae84cbfb2328647e6586107_133) | | | [\[Reserved\]](#i6a987b433ae84cbfb2328647e6586107_133) | | | [75](#i6a987b433ae84cbfb2328647e6586107_133) | | |

Dropped from FY2024

| [PART III](#i6a987b433ae84cbfb2328647e6586107_196) | | | | | | | | |

Dropped from FY2024

| [PART IV](#i6a987b433ae84cbfb2328647e6586107_214) | | | | | | | | |

Dropped from FY2024

| | | | [Signatures](#i6a987b433ae84cbfb2328647e6586107_223) | | | [97](#i6a987b433ae84cbfb2328647e6586107_223) | | |

Dropped from FY2024

“Dexcom”, “Dexcom Clarity”, and “Dexcom One”, and other trademarks of ours appearing in this report are our property.

Dropped from FY2024

- We are subject to risks associated with public health issues, including pandemics, which could have a material adverse effect on our business, financial condition and results of operations.

Item 1C. CYBERSECURITY

4 rewritten, 0 added, 0 removed, 40 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

The processes for assessing, identifying and managing material risks from cybersecurity threats, including threats associated with our use of third-party service [removed: providers,] [added: providers and those that leverage artificial intelligence,] include identifying the relevant assets that could be affected, determining possible threat sources and threat events, assessing threats based on their potential likelihood and impact, and identifying controls that are in place or necessary to manage and/or mitigate such risks.

Rewritten

For example, our Information Security Management System (ISMS) is certified as being in conformity with ISO/IEC 27001 by [removed: SRI Quality System Registrar.][added: PRI Certification.]

Rewritten

Our Board of [removed: Directors] [added: Directors, or the Board,] is responsible for exercising oversight of management’s identification and management of, and planning for, risks from cybersecurity threats.

Rewritten

Our ISO, a co-chair of the committee, has over fifteen years of experience in the field of information security management, having previously led security operations and infrastructure and IT functions for a public university campus and a non-profit organization, and holds several licenses and certifications relating to information security, including a Certified Information Systems Security Manager [added: (CISM)] from the Information Systems Audit and Control Association (ISACA), a Certified Information Systems Security Professional (CISSP) from the International Information Security System Security Certification Consortium (ISC2) and several technical cybersecurity [removed: certifications from the] Global Information Assurance Certification [removed: (GIAC).][added: (GIAC) from the SANS Institute.]

Item 2. PROPERTIES

8 rewritten, 2 added, 7 removed, 1 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

We lease real property [added: throughout the world] to support our business, including manufacturing, research and development, sales, marketing and administration.

Rewritten

The following table sets forth the locations of our [added: corporate headquarters and] manufacturing facilities:

Rewritten

| Mesa, Arizona | | | | | | [removed: 2030 (2)] [added: Manufacturing] | | | [added: | | |]

Rewritten

| Penang, Malaysia | | | | | | [removed: 2082 (3)] [added: Manufacturing] | | | [added: | | |]

Rewritten

| Athenry, [removed: Ireland] [added: Ireland(1)] | | | | | | [removed: 3023 (4)] [added: Manufacturing] | | | [added: | | |]

Rewritten

[removed: Our] [added: | San Diego, California | | | | | | Corporate] headquarters, research and development, and [removed: certain of our] manufacturing [removed: operations are located in San Diego, California.][added: | | | | | |]

Rewritten

[removed: In addition, the construction of a] [added: | (1) Our] new manufacturing facility in Athenry, Ireland is [removed: underway.][added: under construction. | | | | | | | | | | | |]

Rewritten

As of December 31, [removed: 2024,] [added: 2025,] we had approximately [removed: 80,600] [added: 79,700] square feet of laboratory space and approximately 159,600 square feet of controlled environment rooms.

New in FY2025

| Location | | | | | | Purpose | | | | | |

New in FY2025

See Note 5 “*Leases and Other Commitments*” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.

Dropped from FY2024

| Location | | | | | | Lease Expiration Dates | | |

Dropped from FY2024

| San Diego, California | | | | | | 2028 (1) | | |

Dropped from FY2024

| (1) Excludes a renewal that would be at our option to extend the term of a lease expiring in 2028 for one additional three to five-year term. | | | | | | | | |

Dropped from FY2024

| (2) Excludes renewals that would be at our option to extend the term of a lease expiring in 2028 for four additional five-year terms and also excludes renewals that would be at our option to extend the term of a lease expiring in 2030 for two additional five-year terms. | | | | | | | | |

Dropped from FY2024

| (3) Represents 60-year land leases with the state authority expiring at varying dates through 2082. | | | | | | | | |

Dropped from FY2024

| (4) Represents a 999-year land lease with the Industrial Development Agency of Ireland. | | | | | | | | |

Dropped from FY2024

We also lease various manufacturing, administrative, warehouse and customer support real properties throughout the world.

Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

6 rewritten, 9 added, 1 removed, 12 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

We had approximately 25 stockholders of record as of February [removed: 6, 2025.][added: 5, 2026.]

Rewritten

All unregistered sales of equity securities have been previously disclosed in a Form 10-Q or a current report on Form 8-K for the fiscal year ended December 31, [removed: 2024.][added: 2025.]

Rewritten

The graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the S&P Health Care Equipment Select Industry index and the S&P 500 index over the five-year period ended December 31, [removed: 2024.][added: 2025.]

Rewritten

The graph assumes that $100 was invested in Dexcom common stock and in each of the other indices on December 31, [removed: 2019] [added: 2020] and that all dividends were reinvested.

Rewritten

[removed: ![3454](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231_g3.jpg)][added: ![918](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231_g3.jpg)]

Rewritten

* $100 invested on December 31, [removed: 2019] [added: 2020] in stock or index, including reinvestment of any dividends.

New in FY2025

In April 2025, our Board of Directors authorized and approved a share repurchase program of up to $750.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2026 (the “2025 Share Repurchase Program”).

New in FY2025

See Note 8 “*Employee Benefit Plans and Stockholders’ Equity*” to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K for additional information about our share repurchases during the year ended December 31, 2025.

New in FY2025

The following table provides information about purchases by us of our shares of common stock during the three months ended December 31, 2025:

New in FY2025

| Period | | | | | | Total number of shares purchased | | | | | | Average price paid per share(1) | | | | | | Total number of shares purchased as part of publicly announced program(2) | | | | | | Maximum dollar value of shares that may yet be purchased under the program (in millions)(2) | | |

New in FY2025

| 10/01/2025 - 10/31/2025 | | | | | | 875,652 | | | | | | $ | 58.64 | | | | | 875,652 | | | | | | $ | 511.4 | |

New in FY2025

| 11/01/2025 - 11/30/2025 | | | | | | 4,388,845 | | | | | | $ | 59.56 | | | | | 4,388,845 | | | | | | $ | 250.0 | |

New in FY2025

| 12/01/2025 - 12/31/2025 | | | | | | — | | | | | | $ | — | | | | | — | | | | | | $ | 250.0 | |

New in FY2025

| (1) Average price paid per share includes broker commissions. | | | | | | | | | | | | | | | | | | | | | | | | | | |

New in FY2025

| (2) On May 1, 2025, we announced that our Board of Directors authorized and approved a share repurchase program of up to $750.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2026. | | | | | | | | | | | | | | | | | | | | | | | | | | |

Dropped from FY2024

Neither we nor any affiliated purchaser repurchased any of our equity securities during the quarter ended December 31, 2024.

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

0 rewritten, 1 added, 3 removed, 0 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

New in FY2025

The information required by this item is included on pages [F-2](#i863d5bab53004feeb077a051d3498b26_250) to [F-45](#i863d5bab53004feeb077a051d3498b26_520) of this Annual Report and is incorporated herein by reference.

Dropped from FY2024

The information required is set forth under “Report of Independent Registered Public Accounting Firm,” “Consolidated Balance Sheets,” “Consolidated Statements of Operations,” “ Consolidated Statements of Comprehensive Income,” “Consolidated Statements of Stockholders’ Equity,” “Consolidated Statements of Cash Flows” and “Notes to Consolidated Financial Statements” on pages [F-10](#i6a987b433ae84cbfb2328647e6586107_247) to [F-47](#i6a987b433ae84cbfb2328647e6586107_475) of this Annual Report and is incorporated into this Item 8 by reference.

Dropped from FY2024

The report of Dexcom’s independent registered public accounting firm (PCAOB ID:42) with respect to the above-referenced financial statements and their report on internal control over financial reporting are included in Item 8 and Item 9A of this Form 10-K.

Dropped from FY2024

Their consent appears as Exhibit 23.1 of this Form 10-K.

Item 9A. CONTROLS AND PROCEDURES

9 rewritten, 2 added, 2 removed, 34 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

Based on their evaluation as of December 31, [removed: 2024,] [added: 2025,] our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of such date.

Rewritten

Our management, with the participation of [removed: the] [added: our] Chief Executive [added: Officer] and Chief Financial [removed: Officers,] [added: Officer,] assessed the effectiveness of our internal control over financial reporting as of December 31, [removed: 2024.][added: 2025.]

Rewritten

In making this assessment, our management used the criteria set forth by the [removed: 2013] Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated [removed: Framework.][added: Framework (2013).]

Rewritten

Based on this assessment, our management, with the participation of [removed: the] [added: our] Chief Executive [added: Officer] and Chief Financial [removed: Officers,] [added: Officer,] believes that, as of December 31, [removed: 2024,] [added: 2025,] our internal control over financial reporting is effective based on those criteria.

Rewritten

The effectiveness of our internal control over financial reporting as of December 31, [removed: 2024] [added: 2025] has been audited by [removed: Ernst] [added: Deloitte] & [removed: Young] [added: Touche] LLP, an Independent Registered Public Accounting Firm, as stated in their report which is included herein.

Rewritten

We have audited [removed: DexCom, Inc.’s] [added: the] internal control over financial reporting [added: of DexCom, Inc. and subsidiaries (the “Company”)] as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in [removed: Internal Control—Integrated] [added: *Internal Control* — *Integrated] Framework [added: (2013)*] issued by the Committee of Sponsoring Organizations of the Treadway Commission [removed: (2013 framework) (the COSO criteria).][added: (COSO).]

Rewritten

In our opinion, [removed: DexCom, Inc. (the Company)] [added: the Company] maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on [removed: the COSO criteria.][added: criteria established in *Internal Control* — *Integrated Framework (2013)* issued by COSO.]

Rewritten

We [removed: also] have [added: also] audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated [removed: balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated] [added: financial] statements [added: as] of [removed: operations, comprehensive income, stockholders’ equity] and [removed: cash flows] for [removed: each of] the [removed: three years in the period] [added: year] ended December 31, [removed: 2024, and the related notes and financial statement schedule listed in] [added: 2025, of] the [removed: Index at Item 15(a)] [added: Company] and our report dated February [removed: 14, 2025] [added: 12, 2026,] expressed an unqualified opinion [removed: thereon.][added: on those financial statements.]

Rewritten

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial [removed: reporting] [added: reporting,] included in the accompanying Management’s Report on Internal Control over Financial Reporting.

New in FY2025

/s/ Deloitte & Touche LLP

New in FY2025

February 12, 2026

Dropped from FY2024

/s/ Ernst & Young LLP

Dropped from FY2024

February 14, 2025

Item 9B. OTHER INFORMATION

1 rewritten, 8 added, 0 removed, 1 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

[removed: During the three months ended December 31, 2024, no] [added: No] Section 16 officers or directors adopted, modified, or terminated a [removed: “Rule 10b5-1 trading arrangement” or] “non-Rule 10b5-1 trading arrangement” [removed: (each as] [added: (as] defined in Item 408 of Regulation S-K of the Exchange [removed: Act).][added: Act) during the three months ended December 31, 2025.]

New in FY2025

During the three months ended December 31, 2025, the following Section 16 officers and directors adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense of Rule 10b5-1(c):

New in FY2025

| Name | | | Title | | | Action | | | Action Date | | | Aggregate Number of Shares to be Sold | | | Expiration Date(1) | | |

New in FY2025

| Michael J. Brown | | | Executive Vice President, Chief Legal Officer | | | Adoption | | | 11/26/2025 | | | 20,400 | | | 2/26/2027 | | |

New in FY2025

| Jacob S. Leach | | | President, Chief Executive Officer, and Director | | | Termination | | | 11/7/2025 | | | 102,732(2) | | | 3/12/2026 | | |

New in FY2025

| (1) Each trading arrangement permitted or permits transactions through and including the date listed in the table. | | | | | | | | | | | | | | | | | |

New in FY2025

| (2) As of the date of termination, no shares of common stock had been sold under the plan. | | | | | | | | | | | | | | | | | |

New in FY2025

Each of the Rule 10b5-1 trading arrangements disclosed in the above table was made in accordance with our insider trading policy.

New in FY2025

Transactions made pursuant to such trading arrangements will be disclosed publicly in Section 16 filings with the SEC in accordance with applicable securities laws, rules and regulations.

Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

1 rewritten, 0 added, 0 removed, 8 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

The information concerning the Company’s insider trading policies and compliance with Section 16(a) required by this Item is incorporated by reference to the sections of the Proxy Statement entitled “Insider Trading Policy; Anti-Hedging” and “Delinquent Section 16(a) [removed: Reports”,] [added: Reports” (as applicable),] respectively.

Item 11. EXECUTIVE COMPENSATION

1 rewritten, 0 added, 0 removed, 0 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

The information required by this Item concerning executive compensation and our Compensation Committee is incorporated by reference to the sections in the Proxy Statement entitled “Executive Compensation,” [removed: “2024] [added: “2025] Summary Compensation Table,” “Grants of Plan-Based Awards for [removed: 2024,”] [added: 2025,”] “Outstanding Equity Awards at December 31, [removed: 2024,” “2024] [added: 2025,” “2025] Option Exercises and Stock Vested,” “Executive Nonqualified Deferred Compensation Plan,” “Severance and Change in Control Arrangements,” [removed: “2024] [added: “2025] Director Compensation Table,” “Risks from Compensation Policies and Practices,” “Chief Executive Officer Pay Ratio,” “Compensation Committee Interlocks and Insider Participation,” and “Compensation Committee Report.”

Item 15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

14 rewritten, 5 added, 2 removed, 39 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

[Schedule II – Valuation and Qualifying [removed: Accounts](#i6a987b433ae84cbfb2328647e6586107_499).][added: Accounts](#i863d5bab53004feeb077a051d3498b26_526).]

Rewritten

| 4.5 | | | | | | [Description of Securities Registered Under Section 12 of the Exchange Act.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit45.htm) | | | | | | [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 18, 2025] | | | | | | [added: 4.5] | | | | | | [removed: X] | | |

Rewritten

| [removed: 10.13] [added: 10.12] | | | | | | [Amended and Restated Collaboration and License Agreement, dated November 20, 2018, by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences LLC).](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1014-amended.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 8, 2024 | | | | | | 10.14 | | | | | | | | |

Rewritten

| [removed: 10.14] [added: 10.13] | | | | | | [Warrant Termination Agreement between DexCom, Inc. and Bank of America, N.A., dated February 13, 2024.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000024/dxcmexhibit101.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | February 15, 2024 | | | | | | 10.1 | | | | | | | | |

Rewritten

| [removed: 10.16] [added: 10.14] | | | | | | [Confidential Settlement and Patent License [removed: Agreement](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm)[,](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) [dated] [added: Agreement, dated] December 20, [removed: 2024,](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm)[between](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) [Abbott] [added: 2024, between Abbott] Diabetes Care Inc. and DexCom, Inc.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1016.htm) | | | | | | [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 18, 2025] | | | | | | [added: 10.16] | | | | | | [removed: X] | | |

Rewritten

| [removed: 10.17*] [added: 10.18*] | | | | | | [removed: [Amended] [added: [Form of award agreement under the Amended] and Restated 2015 Equity Incentive [removed: Plan and forms of award agreements.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1017.htm)] [added: Plan.](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit1018.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Rewritten

| 19.1* | | | | | | [Insider Trading Policy.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit191.htm) | | | | | | [added: 10-K] | | | | | | [added: 000-51222] | | | | | | [added: February 18, 2025] | | | | | | [added: 19.1] | | | | | | [removed: X] | | |

Rewritten

| 21.1 | | | | | | [List of [removed: Subsidiaries.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit211.htm)] [added: Subsidiaries.](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit211.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Rewritten

| 23.1 | | | | | | [Consent of Independent Registered Public Accounting [removed: Firm.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit231.htm)] [added: Firm (Deloitte & Touche LLP).](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit231.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Rewritten

| 24.1 | | | | | | [Power of Attorney (see signature page of this Form [removed: 10-K).](#i6a987b433ae84cbfb2328647e6586107_223)] [added: 10-K).](#i863d5bab53004feeb077a051d3498b26_244)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Rewritten

| 31.1 | | | | | | [Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit311.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit311.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Rewritten

| 31.2 | | | | | | [Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit312.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit312.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Rewritten

| 32.1* | | | | | | [Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit321.htm)] [added: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit321.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Rewritten

| 32.2* | | | | | | [Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit322.htm)] [added: 13a-14(b).](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit322.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

New in FY2025

| 10.15* | | | | | | [Amended and Restated 2015 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000129/exhibit101-ar2015eip.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 9, 2025 | | | | | | 10.1 | | | | | | | | |

New in FY2025

| 10.16* | | | | | | [Amended and Restated 2015 Employee Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000129/exhibit102-ar2015espp.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 9, 2025 | | | | | | 10.2 | | | | | | | | |

New in FY2025

| 10.17* | | | | | | [Offer Letter, effective January 1, 2026, by and between DexCom, Inc. and Jacob S. Leach.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000291/dxcm20251219-exhibit101.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | December 22, 2025 | | | | | | 10.1 | | | | | | | | |

New in FY2025

| 10.19* | | | | | | [Form of enrollment agreement under the Amended and Restated 2015 Employee Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit1019.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

New in FY2025

| 23.2 | | | | | | [Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP).](https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm12312025-exhibit232.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Dropped from FY2024

| 10.12* | | | | | | [2015 Employee Stock Purchase Plan and forms of subscription agreements.](https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm12312023ex1012-2015emp.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 8, 2024 | | | | | | 10.12 | | | | | | | | |

Dropped from FY2024

| 10.15* | | | | | | [Severance Agreement and General Release, dated October 22, 2024, between DexCom, Inc. and Teri Lawver.](https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm12312024-exhibit1015.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | |

Item 16. FORM 10-K SUMMARY

524 rewritten, 175 added, 234 removed, 594 unchanged

Read the full itemFY2025 item · filed February 12, 2026FY2024 item · filed February 18, 2025

Rewritten

| Dated: February [removed: 14, 2025] [added: 12, 2026] | | | | | | | | | | | | By: | | | | | | /s/ JEREME M. SYLVAIN | | |

Rewritten

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints [removed: Kevin R.][added: Jacob S.]

Rewritten

[removed: Sayer] [added: Leach] and Jereme M.

Rewritten

| /s/ KEVIN R. SAYER | | | | | | [added: Executive] Chairman of the Board of [removed: Directors, President and Chief Executive Officer (Principal Executive Officer)] [added: Directors] | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ JEREME M. SYLVAIN | | | | | | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ MARK G. FOLETTA | | | | | | [added: Interim Chairman of the Board of Directors and] Lead Independent Director | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ STEVEN R. ALTMAN | | | | | | Director | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ NICHOLAS AUGUSTINOS | | | | | | Director | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ RICHARD A. COLLINS | | | | | | Director | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ RIMMA DRISCOLL | | | | | | Director | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ BRIDGETTE P. HELLER | | | | | | Director | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

| /s/ KYLE MALADY | | | | | | Director | | | | | | February [removed: 14, 2025] [added: 12, 2026] | | |

Rewritten

[removed: | [Report of Independent Registered Public Accounting Firm](#i6a987b433ae84cbfb2328647e6586107_229) | | | F-[2](#i6a987b433ae84cbfb2328647e6586107_229) | | |][added: REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM]

Rewritten

| [Consolidated Balance [removed: Sheets](#i6a987b433ae84cbfb2328647e6586107_232)] [added: Sheets](#i863d5bab53004feeb077a051d3498b26_253)] | | | [removed: F-[4](#i6a987b433ae84cbfb2328647e6586107_232)] [added: F-[5](#i863d5bab53004feeb077a051d3498b26_253)] | | |

Rewritten

| [Consolidated Statements of [removed: Operations](#i6a987b433ae84cbfb2328647e6586107_235)] [added: Operations](#i863d5bab53004feeb077a051d3498b26_256)] | | | [removed: F-[5](#i6a987b433ae84cbfb2328647e6586107_235)] [added: F-[6](#i863d5bab53004feeb077a051d3498b26_256)] | | |

Rewritten

| [Consolidated Statements of Comprehensive [removed: Income](#i6a987b433ae84cbfb2328647e6586107_238)] [added: Income](#i863d5bab53004feeb077a051d3498b26_259)] | | | [removed: F-[6](#i6a987b433ae84cbfb2328647e6586107_238)] [added: F-[7](#i863d5bab53004feeb077a051d3498b26_259)] | | |

Rewritten

| [Consolidated Statements of Stockholders’ [removed: Equity](#i6a987b433ae84cbfb2328647e6586107_241)] [added: Equity](#i863d5bab53004feeb077a051d3498b26_262)] | | | [removed: F-[7](#i6a987b433ae84cbfb2328647e6586107_241)] [added: F-[8](#i863d5bab53004feeb077a051d3498b26_262)] | | |

Rewritten

| [Consolidated Statements of Cash [removed: Flows](#i6a987b433ae84cbfb2328647e6586107_244)] [added: Flows](#i863d5bab53004feeb077a051d3498b26_265)] | | | [removed: F-[8](#i6a987b433ae84cbfb2328647e6586107_244)] [added: F-[9](#i863d5bab53004feeb077a051d3498b26_265)] | | |

Rewritten

| [Notes to Consolidated Financial [removed: Statements](#i6a987b433ae84cbfb2328647e6586107_247)] [added: Statements](#i863d5bab53004feeb077a051d3498b26_268)] | | | [removed: F-[10](#i6a987b433ae84cbfb2328647e6586107_247)] [added: F-[11](#i863d5bab53004feeb077a051d3498b26_268)] | | |

Rewritten

We have audited the accompanying consolidated balance [removed: sheets] [added: sheet] of DexCom, Inc. (the Company) as of December 31, [removed: 2024 and 2023,] [added: 2024,] the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the [removed: three] [added: two] years in the period ended December 31, 2024, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”).

Rewritten

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, [removed: 2024 and 2023,] [added: 2024,] and the results of its operations and its cash flows for each of the [removed: three] [added: two] years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

Rewritten

We [removed: also] have [added: also] audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2024,] [added: 2025,] based on criteria established in [removed: Internal Control—Integrated] [added: *Internal Contro*l — *Integrated] Framework [added: (2013)*] issued by the Committee of Sponsoring Organizations of the Treadway Commission [removed: (2013 framework),] and our report dated February [removed: 14, 2025] [added: 12, 2026,] expressed an unqualified opinion [removed: thereon.][added: on the Company’s internal control over financial reporting.]

Rewritten

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and [removed: that:] [added: that] (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, [removed: subjective] [added: subjective,] or complex judgments.

Rewritten

The communication of [removed: the] critical audit [removed: matter] [added: matters] does not alter in any way our opinion on the [removed: consolidated] financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the [removed: account] [added: accounts] or [removed: disclosure] [added: disclosures] to which it relates.

Rewritten

[removed: | | | | | | | Estimation of variable consideration for revenue recognition | | |][added: Revenue Recognition – Variable Consideration to the financial statements]

Rewritten

[removed: | *Description of the Matter* | | | | | | As discussed in Note 1 of the consolidated financial statements, the Company includes an] [added: The] estimate of [removed: variable consideration] [added: pharmacy rebates] in the [removed: calculation of the transaction price at] [added: United States (collectively, “U.S. pharmacy rebates”) involves] the [removed: time] [added: consideration] of [removed: sale. The Company estimates reductions for pharmacy rebates based on] contractual arrangements, estimates of products sold subject to rebate, known events or [removed: trends] [added: trends,] and channel inventory data. [removed: | | |]

Rewritten

We have served as the Company’s auditor since [removed: 2000.][added: 2025.]

Rewritten

| [added: December 31, 2025] | | | [removed: December 31,] | | | | | | | | | [added: | | |]

Rewritten

| [removed: 2024] | | | [added: 2025] | | | [removed: 2023] | | | [added: 2024] | | | [added: | | | 2023 | | |]

Rewritten

| *(In millions, except [removed: share and] par value data)* | | | [added: 2025] | | | | | | [added: 2024] | | |

Rewritten

| Cash and cash equivalents | | | $ | [added: 917.7 | | | | | $ |] 606.1 | | | | | $ | 566.3 | |

Rewritten

| Short-term marketable securities | | | [removed: 1,973.3] [added: 1,081.0] | | | | | | [removed: 2,157.8] [added: 1,973.3] | | |

Rewritten

| Accounts receivable, net | | | [removed: 1,005.7] [added: 1,216.1] | | | | | | [removed: 973.9] [added: 1,005.7] | | |

Rewritten

| Inventory | | | [removed: 542.6] [added: 629.1] | | | | | | [removed: 559.6] [added: 542.6] | | |

Rewritten

| Prepaid and other current assets | | | [removed: 173.7] [added: 189.4] | | | | | | [removed: 168.3] [added: 173.7] | | |

Rewritten

| Total current assets | | | [removed: 4,301.4] [added: 4,033.3] | | | | | | [removed: 4,425.9] [added: 4,301.4] | | |

Rewritten

| Property and equipment, net | | | [removed: 1,339.9] [added: 1,559.9] | | | | | | [removed: 1,113.1] [added: 1,339.9] | | |

Rewritten

| Operating lease right-of-use assets | | | [removed: 62.8] [added: 77.4] | | | | | | [removed: 71.4] [added: 62.8] | | |

Rewritten

| Goodwill | | | [removed: 22.8] [added: 24.2] | | | | | | [removed: 25.2] [added: 22.8] | | |

Rewritten

| Intangibles, net | | | [removed: 103.4] [added: 70.8] | | | | | | [removed: 134.5] [added: 103.4] | | |

New in FY2025

| /s/ JACOB S. LEACH | | | | | | President, Chief Executive Officer, and Director (Principal Executive Officer) | | | | | | February 12, 2026 | | |

New in FY2025

| Jacob S. Leach | | | | | | | | | | | | | | |

New in FY2025

| /s/ DR. EUAN ASHLEY | | | | | | Director | | | | | | February 12, 2026 | | |

New in FY2025

| Dr. Euan Ashley | | | | | | | | | | | | | | |

New in FY2025

| /s/ RENÉE GALÁ | | | | | | Director | | | | | | February 12, 2026 | | |

New in FY2025

| Renée Galá | | | | | | | | | | | | | | |

New in FY2025

| [Report of Independent Registered Public Accounting Firm](#i863d5bab53004feeb077a051d3498b26_250) (PCAOB ID: 34) | | | F-[2](#i863d5bab53004feeb077a051d3498b26_250) | | |

New in FY2025

| [Report of Independent Registered Public Accounting Firm](#i863d5bab53004feeb077a051d3498b26_3782) (PCAOB ID: 42) | | | F-[4](#i863d5bab53004feeb077a051d3498b26_3782) | | |

New in FY2025

We have audited the accompanying consolidated balance sheet of DexCom, Inc. and subsidiaries (the “Company”) as of December 31, 2025, the related consolidated statements of operations, comprehensive income, stockholders’ equity, and cash flows, for the year ended December 31, 2025, and the related notes and the schedule listed in the Index at Item 15(a) (collectively referred to as the “financial statements”).

New in FY2025

In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

New in FY2025

Our responsibility is to express an opinion on the Company’s financial statements based on our audit.

New in FY2025

We conducted our audit in accordance with the standards of the PCAOB.

New in FY2025

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.

New in FY2025

Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.

New in FY2025

We believe that our audit provides a reasonable basis for our opinion.

New in FY2025

Pharmacy Rebates in the United States — Refer to Note 1.

New in FY2025

Critical Audit Matter Description

New in FY2025

As disclosed in Note 1 to the financial statements, when revenue is recognized, the Company includes an estimate of variable consideration in the calculation of the transaction price.

New in FY2025

Variable consideration includes, but is not limited to, rebates, chargebacks, product returns provision, and prompt payment discounts.

New in FY2025

The Company classifies these items as a liability unless the criteria for right of offset are met; in such cases, the Company may classify these items as a reduction of accounts receivable.

New in FY2025

The Company is subject to rebates on pricing programs with managed care organizations, such as pharmacy benefit managers, government, and third-party payors.

New in FY2025

Given the subjectivity and complexity of evaluating management’s assumptions used in the estimation of U.S. pharmacy rebates, auditing U.S. pharmacy rebates requires a high degree of auditor judgment and an increased extent of effort.

New in FY2025

*How the Critical Audit Matter Was Addressed in the Audit*

New in FY2025

Our audit procedures related to the U.S. pharmacy rebates included the following, among others:

New in FY2025

- We tested the effectiveness of certain controls related to management’s assessment of assumptions related to estimating the U.S. pharmacy rebates reserve and the associated variable consideration.

New in FY2025

- We evaluated the appropriateness and consistency of the Company’s methods and assumptions used to calculate the U.S. pharmacy rebates reserve and the associated variable consideration by:

New in FY2025

◦Testing the underlying data, including historical and current year gross sales to distributor customers, rebate payments, and inventory sold reported from distributors.

New in FY2025

◦Evaluating the Company’s ability to estimate the U.S. pharmacy rebates accrual accurately by comparing actual amounts incurred for the U.S. pharmacy rebates accruals to historical estimates.

New in FY2025

◦Evaluating known events or trends affecting the U.S. pharmacy rebates.

New in FY2025

/s/ Deloitte & Touche LLP

New in FY2025

San Diego, CA

New in FY2025

February 12, 2026

New in FY2025

To the Stockholders and the Board of Directors of DexCom, Inc.

New in FY2025

Opinion on the Financial Statements

New in FY2025

Basis for Opinion

New in FY2025

These financial statements are the responsibility of the Company’s management.

New in FY2025

We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

New in FY2025

Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

New in FY2025

Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

New in FY2025

We served as the Company’s auditor from 2000 to 2025.

Dropped from FY2024

| /s/ KAREN DAHUT | | | | | | Director | | | | | | February 14, 2025 | | |

Dropped from FY2024

| Karen Dahut | | | | | | | | | | | | | | |

Dropped from FY2024

| /s/ ERIC J. TOPOL | | | | | | Director | | | | | | February 14, 2025 | | |

Dropped from FY2024

| Eric J. Topol, M.D. | | | | | | | | | | | | | | |

Dropped from FY2024

| | | | Auditing management’s determination of variable consideration relating to pharmacy rebates involved a high degree of subjectivity in evaluating management’s estimates. In estimating pharmacy rebates, management applies contracted rates to estimates of products sold subject to rebate, known market events or trends and channel inventory data. | | | | | |

Dropped from FY2024

| *How We Addressed the Matter in Our Audit* | | | | | | We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company’s processes to determine pharmacy rebates, including the underlying assumptions. | | |

Dropped from FY2024

| | | | Our audit procedures also included, among others, evaluating the significant assumptions and the accuracy and completeness of the underlying data used in management’s calculations. This included testing contractual rates, management’s estimates of products sold subject to rebate, and inventory held by third parties at the end of the period, through a combination of underlying data validation by inspection of source documents, agreement to underlying contracts, and review for consistency against historical data. In addition, we inspected the results of the Company’s analysis of pharmacy rebates claimed and evaluated the estimates made based on historical experience. | | | | | |

Dropped from FY2024

| Deferred revenue | | | 8.0 | | | | | | 18.4 | | |

Dropped from FY2024

| Balance at December 31, 2021 | | | | | | 388.0 | | | | | | $ | 0.4 | | | | | $ | 2,108.7 | | | | | | | | | | | | | | | | | $ | 0.5 | | | | | $ | 138.7 | | | | | $ | (206.2) | | | | | $ | 2,042.1 | |

Dropped from FY2024

| Purchases of treasury stock | | | | | | (6.6) | | | | | | — | | | | | | — | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | (557.7) | | | | | | (557.7) | | |

Dropped from FY2024

| Conversions of 2023 Notes | | | | | | 0.4 | | | | | | — | | | | | | 4.2 | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | 13.2 | | | | | | 17.4 | | |

Dropped from FY2024

| Capitalization of sales-based milestones | | | | | | — | | | | | | — | | | | | | 152.4 | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | 152.4 | | |

Dropped from FY2024

| Tax benefit related to Senior Convertible Notes | | | | | | — | | | | | | — | | | | | | (4.4) | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | — | | | | | | (4.4) | | |

Dropped from FY2024

| Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs | | | | | | 1.5 | | | | | | — | | | | | | (188.1) | | | | | | | | | | | | | | | | | | — | | | | | | — | | | | | | 188.1 | | | | | | — | | |

Dropped from FY2024

| Acquisitions, net of cash acquired | | | — | | | | | | — | | | | | | (3.9) | | |

Dropped from FY2024

| Shares received under note hedge upon conversion of 2023 Notes | | | $ | — | | | | | $ | (1,490.3) | | | | | $ | (33.5) | |

Dropped from FY2024

We do not generally intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.

Dropped from FY2024

| Customer D | | | 42 | | % | | | | 37 | | % | | | | 29 | | % | | | | 27 | | % | | | | 27 | | % |

Dropped from FY2024

| Customer E | | | * | | | | | | * | | | | | | 10 | | % | | | | * | | | | | | * | | |

Dropped from FY2024

* Less than 10%

Dropped from FY2024

Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business, and an adverse action or assessment by a regulator.

Dropped from FY2024

We perform our goodwill impairment analysis at the reporting unit level, which aligns with Dexcom’s reporting structure and the availability of discrete financial information.

Dropped from FY2024

We perform the first step of our annual impairment analysis by either comparing a reporting unit’s estimated fair value to its carrying amount or doing a qualitative assessment of a reporting unit’s fair value from the last quantitative assessment to determine if there is potential impairment.

Dropped from FY2024

We may do a qualitative assessment when the results of the previous quantitative test indicated the reporting unit’s estimated fair value was significantly in excess of the carrying value of its net assets and we do not believe there have been significant changes in the reporting unit’s operations that would significantly decrease its estimated fair value or significantly increase its net assets.

Dropped from FY2024

If a quantitative assessment is performed the evaluation includes management estimates of cash flow projections based on internal future projections and/or use of a market approach by looking at market values of comparable companies.

Dropped from FY2024

Key assumptions for these projections include revenue growth, future gross margin and operating margin growth, and weighted cost of capital and terminal growth rates.

Dropped from FY2024

The revenue and margin growth are based on increased sales of new and existing products as we maintain investments in research and development.

Dropped from FY2024

Additional assumed value creators may include increased efficiencies from capital spending.

Dropped from FY2024

The resulting cash flows are discounted using a weighted average cost of capital.

Dropped from FY2024

Operating mechanisms and requirements to ensure that growth and efficiency assumptions will ultimately be realized are also considered in the evaluation, including the timing and probability of regulatory approvals for our products to be commercialized.

Dropped from FY2024

We also consider Dexcom’s market capitalization as a part of our analysis.

Dropped from FY2024

If the estimated fair value of a reporting unit exceeds the carrying amount of the net assets assigned to that unit, goodwill is not impaired and no further analysis is required.

Dropped from FY2024

If the carrying value of the net assets assigned to a reporting unit exceeds the estimated fair value of the unit, we perform the second step of the impairment test.

Dropped from FY2024

In this step we allocate the fair value of the reporting unit calculated in step one to all of the assets and liabilities of that unit, as if we had just acquired the reporting unit in a business combination.

Dropped from FY2024

The excess of the fair value of the reporting unit over the total amount allocated to the assets and liabilities represents the implied fair value of goodwill.

Dropped from FY2024

If the carrying amount of a reporting unit’s goodwill exceeds its implied fair value, we would record an impairment loss equal to the difference.

Dropped from FY2024

Transaction price is typically based on the contracted rates less an estimate of claim denials and historical reimbursement experience by payor, which include current and future expectations regarding reimbursement rates and payor mix.

Dropped from FY2024

We classify these items as a reduction of accounts receivable when we are not required to make a payment and as a liability when we are required to make a payment.

Dropped from FY2024

The deferred revenue balances related to performance obligations that will be satisfied after twelve months were $9.5 million as of December 31, 2024 and $7.4 million as of December 31, 2023.

Dropped from FY2024

In periods of net losses, we exclude all potentially dilutive common shares from the computation of the diluted net loss per share for those periods as the effect would be anti-dilutive.

An excerpt. Shown here: 40 of 524 rewritten, 40 of 175 added and 40 of 234 removed. The counts are complete. For every sentence, read Item 16. FORM 10-K SUMMARY in the FY2025 filing and the FY2024 filing.